<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00226499</url>
  </required_header>
  <id_info>
    <org_study_id>100388</org_study_id>
    <secondary_id>104105 (EXT FU Y2)</secondary_id>
    <secondary_id>103494 (EXT FU Y1)</secondary_id>
    <secondary_id>104106 (EXT FU Y4-Y6-Y8-Y10)</secondary_id>
    <secondary_id>2004-002676-41</secondary_id>
    <nct_id>NCT00226499</nct_id>
  </id_info>
  <brief_title>Evaluate Vaccine Against Chickenpox and a Combined Vaccine Against 4 Viral Childhood Diseases: Measles, Mumps, Rubella and Chickenpox</brief_title>
  <official_title>Study in Healthy Children (&lt;2 Years) to Evaluate the Safety and Efficacy of GSK Biologicals' Live Attenuated Varicella Vaccine (VarilrixTM) and of GSK Biologicals' Combined Measles-Mumps-Rubella-Varicella Vaccine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      An observer-blind study to evaluate GlaxoSmithKline Biologicals' live attenuated varicella
      vaccine and GlaxoSmithKline Biologicals' combined measles-mumps-rubella-varicella vaccine in
      the prevention of varicella disease in children. The Protocol Posting has been updated in
      order to comply with the FDA Amendment Act, Sep 2007.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      According to treatment group allocation, participants will receive study vaccines and be
      followed for antibody titres and occurrence of varicella disease.

      This study is conducted in 2 phases. Phase A includes the vaccination period and an
      observation period for efficacy. The efficacy endpoints will be evaluated over at least two
      years after vaccination. During this period, the immunogenicity endpoints will be evaluated
      with respect to the immune response 43 days after vaccination and the persistence of
      antibodies over two years to varicella (for all subjects) and to measles, mumps and rubella
      (for a subset of subjects). Regarding the safety endpoints, SAEs (including any complicated
      varicella cases if observed) will be assessed for all subjects during the whole Phase A
      duration, whereas, solicited (local and general) and unsolicited adverse events will be
      assessed in a subset of subjects within a 43-day period after vaccination.

      Phase B is an extension of Phase A. It is a long-term follow-up until Year 10 to examine the
      long-term efficacy of the study vaccines against clinical varicella disease as well as the
      long-term persistence of antibodies to varicella (for all subjects) and to measles, mumps and
      rubella (in a subset of subjects) after vaccination.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 1, 2005</start_date>
  <completion_date type="Actual">October 12, 2006</completion_date>
  <primary_completion_date type="Actual">October 12, 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase A: Number of Subjects With Confirmed Varicella Case</measure>
    <time_frame>From 42 days post dose 2 until the end of Phase A</time_frame>
    <description>Confirmed varicella case = A case that met the clinical case definition [an illness with acute onset of diffuse, generalized maculopapulovesicular rash (i.e. spots, papules and/or vesicles) without other apparent cause] at least in the opinion of the investigator and was confirmed by laboratory test [Polymerase Chain Reaction (PCR) (+)] OR a case that met the clinical definition confirmed by the Independent Data Monitoring Committee (IDMC) and was epidemiologically linked [Epi (+)] to a valid index case.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase A: Number of Subjects With Moderate or Severe Confirmed Varicella Case</measure>
    <time_frame>From 42 days post dose 2 until the end of Phase A</time_frame>
    <description>Confirmed varicella case: A case that met the clinical case definition at least in the opinion of the investigator and was confirmed by laboratory test [PCR (+)] OR a case that met the clinical definition confirmed by the IDMC and was epidemiologically linked [Epi (+)] to a valid index case. Moderately severe disease: 8-15 points; severe disease: ≥ 16 points (scored by IDMC using the modified Vázquez scale).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase A: Number of Subjects With Probable or Confirmed Varicella Case</measure>
    <time_frame>From 42 days post dose 2 until the end of Phase A</time_frame>
    <description>Probable or confirmed varicella case = A case that met the clinical case definition (as determined by the IDMC) but was not laboratory confirmed [PCR (‑)] AND was not epidemiologically linked [Epi (‑)] to another probable or confirmed case.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase A: Immune Response to Varicella Vaccine With Respect to Anti-Varicella Zoster Virus (Anti-VZV) Antibody Concentrations</measure>
    <time_frame>At Day 0, Day 42, Day 84, Year 1 and Year 2 time points</time_frame>
    <description>Anti-VZV antibody concentrations are presented as Geometric Mean Concentrations (GMCs), expressed in milliinternational units per milliliter (mIU/mL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase A: Number of Subjects With Seroconversion/Seroresponse to VZV</measure>
    <time_frame>At Day 0, Day 42, Day 84, Year 1 and Year 2 time points</time_frame>
    <description>Seronegative (S-) = Subjects with antibody concentration less than (&lt;) 25 mIU/mL prior to vaccination. Seropositive (S+) = Subjects with antibody concentration greater than or equal to (≥) 25 mIU/mL prior to vaccination. Seroconversion was defined as the appearance of antibodies (i.e. titer greater than or equal to the cut-off value) in the serum of subjects seronegative before vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase A: Immune Response to Measles With Respect to Anti-measles Antibody Concentrations in a Subset of Subjects</measure>
    <time_frame>At Day 0, Day 42, Day 84, Year 1 and Year 2 time points</time_frame>
    <description>Anti-measles antibody concentrations are presented as Geometric Mean Concentrations (GMCs), expressed in milliinternational units per milliliter (mIU/mL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase A: Number of Subjects With Seroconversion/Seroresponse to Measles in a Subset of Subjects</measure>
    <time_frame>At Day 0, Day 42, Day 84, Year 1 and Year 2 time points</time_frame>
    <description>Seronegative (S-) = Subjects with antibody concentration &lt; 150 mIU/mL prior to vaccination. Seropositive (S+) = Subjects with antibody concentration ≥ 150 mIU/mL prior to vaccination. Seroconversion was defined as the appearance of antibodies (i.e. titer greater than or equal to the cut-off value) in the serum of subjects seronegative before vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase A: Immune Response to Mumps With Respect to Anti-mumps Antibody Concentrations in a Subset of Subjects</measure>
    <time_frame>At Day 0, Day 42, Day 84, Year 1 and Year 2 time points</time_frame>
    <description>Anti-mumps antibody concentrations are presented as Geometric Mean Concentrations (GMCs), expressed in units per milliliter (U/mL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase A: Number of Subjects With Seroconversion/Seroresponse to Mumps in a Subset of Subjects</measure>
    <time_frame>At Day 0, Day 42, Day 84, Year 1 and Year 2 time points</time_frame>
    <description>Seronegative (S-) = Subjects with antibody concentration &lt; 231 U/mL prior to vaccination. Seropositive (S+) = Subjects with antibody concentration ≥ 231 U/mL prior to vaccination. Seroconversion was defined as the appearance of antibodies (i.e. titer greater than or equal to the cut-off value) in the serum of subjects seronegative before vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase A: Immune Response to Rubella With Respect to Anti-rubella Antibody Concentrations in a Subset of Subjects</measure>
    <time_frame>At Day 0, Day 42, Day 84, Year 1 and Year 2 time points</time_frame>
    <description>Anti-rubella antibody concentrations are presented as Geometric Mean Concentrations (GMCs), expressed in International Units per milliliter (IU/mL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase A: Number of Subjects With a Seroconversion/Seroresponse to Rubella in a Subset of Subjects</measure>
    <time_frame>At Day 0, Day 42, Day 84, Year 1 and Year 2 time points</time_frame>
    <description>Seronegative (S-) = Subjects with antibody concentration &lt; 4 IU/mL prior to vaccination. Seropositive (S+) = Subjects with antibody concentration ≥ 4 IU/mL prior to vaccination. Seroconversion was defined as the appearance of antibodies (i.e. titer greater than or equal to the cut-off value) in the serum of subjects seronegative before vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase A: Number of Subjects With Confirmed Cases of Herpes Zoster</measure>
    <time_frame>From Day 0 until the end of Phase A (Year 2)</time_frame>
    <description>The number of subjects with confirmed cases of herpes zoster is reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase A: Number of Subjects Reporting Fever</measure>
    <time_frame>Within 43 days (Day 0-42) post-vaccination period following each dose</time_frame>
    <description>All fever = Occurrence of any fever (measured rectally) regardless of its intensity grade or relationship to vaccination. Related = fever (measured rectally) assessed by the investigator to be causally related to the study vaccination. Medical Advice = seek for medical advice.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase A: Number of Subjects Reporting Fever</measure>
    <time_frame>Within 15 days (Day 0-14) post-vaccination period following each dose</time_frame>
    <description>All fever = Occurrence of any fever (measured rectally) regardless of its intensity grade or relationship to vaccination. Related fever = fever (measured rectally) assessed by the investigator to be causally related to the study vaccination. Medical Advice = seek for medical advice.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase A: Number of Subjects Reporting Solicited Local Symptoms</measure>
    <time_frame>4 days post-vaccination period following each dose</time_frame>
    <description>Solicited local symptoms assessed were pain, redness and swelling. Any solicited local symptom = Occurrence of any local symptom regardless of their intensity grade. Grade 3 pain = Cried when limb was moved/spontaneously painful. Grade 3 redness and swelling = greater than (&gt;) 20 mm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase A: Number of Subjects Reporting Meningism</measure>
    <time_frame>Within 43 days (Day 0-42) post-vaccination period following each dose</time_frame>
    <description>Any = Occurrence of meningism regardless of its intensity grade. Grade 3 meningism = Prevented normal, everyday activities. Related = Assessed by the investigator to be causally related to the study vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase A: Number of Subjects Reporting Parotitis</measure>
    <time_frame>Within 43 days (Day 0-42) post-vaccination period following each dose</time_frame>
    <description>Any = Occurrence of parotitis regardless of its intensity grade. Grade 3 parotitis = Swelling with accompanying general symptoms. Related = Assessed by the investigator to be causally related to the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase A: Number of Subjects Reporting Rash</measure>
    <time_frame>Within 43 days (Day 0-42) post-vaccination period following each dose</time_frame>
    <description>Any = Occurrence of rash regardless of its intensity grade. Grade 3 rash = 101-500 lesions. Grade 4 rash = &gt; 500 lesions. Related rash = Assessed by the investigator to be causally related to the study vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase A: Number of Subjects With Suspected Sign of Meningism Including Febrile Convulsions</measure>
    <time_frame>Within 43 days (Day 0-42) post-vaccination period following each dose</time_frame>
    <description>Any = Occurrence of meningism including febrile convulsions regardless of intensity grade.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase A: Number of Subjects Reporting Unsolicited Adverse Events (AEs)</measure>
    <time_frame>Within 43 days (Day 0-42) post-vaccination period following each dose</time_frame>
    <description>Unsolicited AE assessed included any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any = Occurrence of any unsolicited symptom regardless of intensity grade or relation to vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase A: Number of Subjects Reporting Serious Adverse Events (SAEs)</measure>
    <time_frame>From Day 0 until the end of Phase A (Year 2)</time_frame>
    <description>SAEs assessed included medical occurrences that resulted in death, were life-threatening, required hospitalisation or prolongation of hospitalisation or resulted in disability/incapacity. Any SAE = occurrence of SAE regardless of intensity grade or relation to vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase A: Health Economics Analysis of Factors Leading to Indirect Costs Due to Varicella Illness</measure>
    <time_frame>During Phase A (from Day 0 up to Year 2)</time_frame>
    <description>Parameters assessed: 1. Number of hours lost from work by parents/guardians as a result of taking care of their child due to varicella. 2. Number of hours the child lost attendance in: day care/childminder, school, or in any extra-curricular activities (e.g. sports or recreation or any type of organised leisure activities) due to varicella. 3. Number of hours spent by a nurse, a babysitter or any type of existing paid caregiver to look after the child (if applicable).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase B: Number of Subjects With Confirmed Varicella Case</measure>
    <time_frame>From the beginning of Phase B (Year 2) up to study end (Year 10)</time_frame>
    <description>Confirmed varicella case = A case that met the clinical case definition at least in the opinion of the investigator and was confirmed by laboratory test [PCR (+)] OR a case that met the clinical definition confirmed by the IDMC and was epidemiologically linked [Epi (+)] to a valid index case.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase B: Number of Subjects With Moderate or Severe Confirmed Varicella Case</measure>
    <time_frame>From the beginning of Phase B (Year 2) up to study end (Year 10)</time_frame>
    <description>Confirmed varicella case = A case that met the clinical case definition at least in the opinion of the investigator and was confirmed by laboratory test [PCR (+)] OR a case that met the clinical definition confirmed by the IDMC and was epidemiologically linked [Epi (+)] to a valid index case. Moderately severe disease = 8-15 points; severe disease: ≥ 16 points (scored by IDMC using the modified Vázquez scale).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase B: Number of Subjects With Probable or Confirmed Varicella Case</measure>
    <time_frame>From the beginning of Phase B (Year 2) up to study end (Year 10)</time_frame>
    <description>Probable or confirmed varicella = A case that met the clinical case definition (as determined by the IDMC) but was not laboratory confirmed [PCR (‑)] AND was not epidemiologically linked [Epi (‑)] to another probable or confirmed case.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase B: Characteristics of Varicella Cases</measure>
    <time_frame>From the beginning of Phase B (Year 2) up to study end (Year 10)</time_frame>
    <description>Varicella cases were characterized by type, number and character of lesions, duration of rash, incidence of fever, systemic signs, the assessment by investigator, complications, treatment, outcome and intensity of severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase B: Immune Response to Varicella Vaccine With Respect to Anti-Varicella Zoster Virus (Anti-VZV) Antibody Concentrations</measure>
    <time_frame>At Year 4, Year 6, Year 8 and Year 10 time points</time_frame>
    <description>Anti-VZV antibody concentrations are presented as Geometric Mean Concentrations (GMCs), expressed in milliinternational units per milliliter (mIU/mL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase B: Number of Subjects With Anti-VZV Antibody Concentrations Above the Cut-off Value</measure>
    <time_frame>At Year 4, Year 6, Year 8 and Year 10 time points</time_frame>
    <description>The anti-VZV antibody concentration cut-off value assessed was greater than or equal to (≥) 25 mIU/mL, in the sera of subjects seronegative before vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase B: Immune Response to Measles With Respect to Anti-measles Antibody Concentrations</measure>
    <time_frame>At Year 4, Year 6, Year 8 and Year 10 time points</time_frame>
    <description>Anti-measles antibody concentrations are presented as Geometric Mean Concentrations (GMCs), expressed in milliinternational units per milliliter (mIU/mL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase B: Number of Subjects With Anti-measles Antibody Concentrations Above the Cut-off Value</measure>
    <time_frame>At Year 4, Year 6, Year 8 and Year 10 time points</time_frame>
    <description>The anti-measles antibody concentration cut-off value assessed was ≥ 150 mIU/mL, in the sera of subjects seronegative before vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase B: Immune Response to Mumps With Respect to Anti-mumps Antibody Concentrations</measure>
    <time_frame>At Year 4, Year 6, Year 8 and Year 10 time points</time_frame>
    <description>Anti-mumps antibody concentrations are presented as Geometric Mean Concentrations (GMCs), expressed in units per milliliter (U/mL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase B: Number of Subjects With Anti-mumps Antibody Concentrations Above the Cut-off Value</measure>
    <time_frame>At Year 4, Year 6, Year 8 and Year 10 time points</time_frame>
    <description>The anti-mumps antibody concentration cut-off value assessed was ≥ 231 U/mL, in the sera of subjects seronegative before vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase B: Immune Response to Rubella With Respect to Anti-rubella Antibody Concentrations</measure>
    <time_frame>At Year 4, Year 6, Year 8 and Year 10 time points</time_frame>
    <description>Anti-rubella antibody concentrations are presented as Geometric Mean Concentrations (GMCs), expressed in international units per milliliter (IU/mL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase B: Number of Subjects With Anti-rubella Antibody Concentrations Above the Cut-off Value</measure>
    <time_frame>At Year 4, Year 6, Year 8 and Year 10 time points</time_frame>
    <description>The anti-rubella antibody concentration cut-off value assessed was ≥ 4 IU/mL, in the sera of subjects seronegative before vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase B: Characteristics of Zoster Cases</measure>
    <time_frame>From 6 weeks after Dose 2 until study end (Year 10)</time_frame>
    <description>Zoster cases were characterized by number and character of lesions, duration of rash, incidence of fever, systemic signs, the assessment by investigator, complications, treatment, outcome and intensity of severity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase B: Number of Subjects Reporting Serious Adverse Events (SAEs)</measure>
    <time_frame>From the beginning of Phase B (Year 2) up to study end (Year 10)</time_frame>
    <description>SAEs assessed included medical occurrences that resulted in death, were life-threatening, required hospitalisation or prolongation of hospitalisation or resulted in disability/incapacity. Any SAE = occurrence of SAE regardless of intensity grade or relation to vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase B: Health Economics Analysis of Factors Leading to Indirect Costs Due to Varicella Illness</measure>
    <time_frame>During Phase B</time_frame>
    <description>Parameters assessed: 1. Number of hours lost from work by parents/guardians as a result of taking care of their child due to varicella. 2. Number of hours the child lost attendance in: day care/childminder, school, or in any extra-curricular activities (e.g. sports or recreation or any type of organised leisure activities) due to varicella. 3. Number of hours spent by a nurse, a babysitter or any type of existing paid caregiver to look after the child (if applicable).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">5803</enrollment>
  <condition>Varicella</condition>
  <condition>Chickenpox Vaccines</condition>
  <arm_group>
    <arm_group_label>MMRV Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in this group received 2 doses of Priorix-Tetra vaccine, administered subcutaneously in the deltoid region of the left arm, one at Day 0 (Visit 1) and the other at Day 42 (Visit 2).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OKAH Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in this group received 1 dose of Priorix at Day 0 (Visit 1) and 1 dose of Varilrix at Day 42 (Visit 2). Both vaccines were administered subcutaneously in the deltoid region of the left arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MMR Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects in this group received 2 doses of Priorix, administered subcutaneously in the deltoid region of the left arm, one at Day 0 (Visit 1) and the other at Day 42 (Visit 2).</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Priorix-tetra™</intervention_name>
    <description>2 doses administered subcutaneously, one at Day 0 and the other at Day 42 to subjects in MMRV Group</description>
    <arm_group_label>MMRV Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Priorix™</intervention_name>
    <description>2 doses administered subcutaneously, one at Day 0 and the other at Day 42 to subjects in MMR Group and one dose administered subcutaneously at Day 0 to subjects in OKAH Group</description>
    <arm_group_label>MMR Group</arm_group_label>
    <arm_group_label>OKAH Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Varilrix™</intervention_name>
    <description>1 dose administered subcutaneously at Day 42 to subjects in OKAH Group</description>
    <arm_group_label>OKAH Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Subjects for whom the investigator believes that their parents/guardians can and will
             comply with the requirements of the protocol for the whole duration of the study.

          -  Male or female subject between 12 and 22 months of age at the time of the first
             vaccination.

          -  Subjects free of obvious health problems, as established by medical history and
             physical examination before entering the study.

          -  Written informed consent obtained from the parents/guardians of the subject after they
             have been informed on the risks and benefits of the study, in a language they clearly
             understand and before performance of any study procedure.

          -  Subjects whose parents/guardians have direct access to telephone/mobile phone.

          -  Subjects:

               1. with at least one sibling (with negative history of varicella
                  disease/vaccination) at home, or

               2. attending day care center, or

               3. attending childminders, i.e. someone taking care of several children, or

               4. who are in contact for at least once a week with other children without a known
                  positive history of varicella disease/vaccination, while playing in close
                  physical contact for more than 5 minutes.

        Exclusion criteria:

          -  Previous vaccination against measles, mumps, rubella and/or varicella.

          -  History of previous measles, mumps, rubella and/or varicella/ herpes zoster diseases.

          -  Known exposure to measles, mumps, rubella and/or varicella/herpes zoster within 30
             days prior to the start of the study.

          -  Chronic administration (defined as more than 14 days) of immunosuppressants or other
             immune-modifying drugs within six months prior to the first vaccine dose.

          -  Administration of immunoglobulins and/or any blood products within three months prior
             to the first vaccine dose or planned administration during the study period.

          -  Any confirmed or suspected immunosuppressive or immunodeficient condition, based on
             medical history and physical.

          -  Family history of congenital or hereditary immunodeficiency.

          -  History of allergic diseases or reactions likely to be exacerbated by any component of
             the vaccines, including systemic allergy to egg proteins or neomycin.

          -  Major congenital defects or serious chronic illness.

          -  Residence in the same household as newborns (0-4 weeks of age), pregnant women who are
             varicella-susceptible, persons with a known immunodeficiency or any other persons at
             high risk for varicella.

          -  History of any neurologic disorders or seizures.

          -  Use of any investigational or non-registered product (drug/vaccine other than the
             study vaccines) within 14 days prior to vaccination and planned use during the study
             period.

        Additional exclusion criteria for subjects included in the subset:

        - Administration of a licensed vaccine within 14 days prior to vaccination and planned use
        until approximately 42 days after the last study vaccine dose (Day 84) with the exception
        of oral polio vaccine (OPV).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>11 Months</minimum_age>
    <maximum_age>22 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Brno</city>
        <zip>628 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chomutov</city>
        <zip>43003</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Decin</city>
        <zip>405 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Havlickuv Brod</city>
        <zip>580 22</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hradec Kralove</city>
        <zip>500 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Humpolec</city>
        <zip>396 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Jindrichuv Hradec</city>
        <zip>377 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kolin</city>
        <zip>28002</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Liberec</city>
        <zip>46015</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Moravska Ostrava</city>
        <zip>702 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nachod</city>
        <zip>547 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ostrava</city>
        <zip>728 92</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pardubice</city>
        <zip>532 03</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Plzen</city>
        <zip>305 99</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Praha 4</city>
        <zip>140 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Praha 4</city>
        <zip>14200</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Praha 5</city>
        <zip>150 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Praha 6</city>
        <zip>160 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Praha 9</city>
        <zip>190 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Znojmo</city>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Arta</city>
        <zip>471 00</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Athens</city>
        <zip>115 22</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Athens</city>
        <zip>115 27</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Athens</city>
        <zip>25236</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Giannitsa</city>
        <zip>581 00</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Karditsa</city>
        <zip>43100</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Komotini</city>
        <zip>69 100</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ptolemaida</city>
        <zip>50200</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Thessaloniki</city>
        <zip>54636</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tripolis</city>
        <zip>22100</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Veria</city>
        <zip>591 00</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Quarto (NA)</city>
        <state>Campania</state>
        <zip>80010</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ferrara</city>
        <state>Emilia-Romagna</state>
        <zip>44100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Udine</city>
        <state>Friuli-Venezia-Giulia</state>
        <zip>33100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Genova</city>
        <state>Liguria</state>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Novara</city>
        <state>Piemonte</state>
        <zip>28100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Alghero (SS)</city>
        <state>Sardegna</state>
        <zip>07041</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ozieri (SS)</city>
        <state>Sardegna</state>
        <zip>07014</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Firenze</city>
        <state>Toscana</state>
        <zip>50139</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Alytus</city>
        <zip>LT-63164</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kaunas</city>
        <zip>LT-48259</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Klaipeda</city>
        <zip>LT-94007</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Panevezys</city>
        <zip>LT-37355</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Siauliai</city>
        <zip>LT-76346</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Vilnius</city>
        <zip>LT -10207</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Vilnius</city>
        <zip>LT-02169</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Vilnius</city>
        <zip>LT-11200</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bekkestua</city>
        <zip>1319</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Moelv</city>
        <zip>N-2390</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Paradis</city>
        <zip>5231</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Skien</city>
        <zip>N-03730</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Trondheim</city>
        <zip>N-7036</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-021</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Debica</city>
        <zip>39-200</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Krakow</city>
        <zip>31-202</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Olesnica</city>
        <zip>56-400</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Poznan</city>
        <zip>61-709</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Siemianowice Slaskie</city>
        <zip>41-103</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tarnow</city>
        <zip>33-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Trzebnica</city>
        <zip>55-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wesola</city>
        <zip>05-077</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wroclaw</city>
        <zip>52-312</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Brasov</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bucharest</city>
        <zip>050098</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bucharest</city>
        <zip>077190</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bucharest</city>
        <zip>20395</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bucharest</city>
        <zip>22102</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cluj-Napoca</city>
        <zip>400217</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Constanta</city>
        <zip>900709</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sibiu</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Timisoara</city>
        <zip>300593</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ekaterinburg</city>
        <zip>620085</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ekaterinburg</city>
        <zip>620109</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ivanteevka Moscow Region</city>
        <zip>141280</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Moscow</city>
        <zip>115 478</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Moscow</city>
        <zip>115446</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Moscow</city>
        <zip>119991</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Murmansk</city>
        <zip>183046</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Novokuznetsk</city>
        <zip>654063</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630112</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Samara</city>
        <zip>443079</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sankt-Peterburg</city>
        <zip>191123</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Saratov</city>
        <zip>410010</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tomsk</city>
        <zip>634001</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Volgograd</city>
        <zip>400130</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bratislava</city>
        <zip>841 08</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bratislava</city>
        <zip>851 05</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dlha nad Oravou</city>
        <zip>027 55</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dolny Kubin</city>
        <zip>026 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dubnica Nad Vahom</city>
        <zip>018 41</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nova Dubnica</city>
        <zip>018 51</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nove Mesto nad Vahom</city>
        <zip>915 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nove Zamky</city>
        <zip>940 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Puchov</city>
        <zip>020 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ruzomberok</city>
        <zip>034 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sturovo</city>
        <zip>943 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Surany</city>
        <zip>942 18</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Trencin</city>
        <zip>911 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Linköping</city>
        <zip>SE-581 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Malmö</city>
        <zip>205 02</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Norrköping</city>
        <zip>SE-602 39</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Umeå</city>
        <zip>SE-901 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Örebro</city>
        <zip>SE-702 11</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>Greece</country>
    <country>Italy</country>
    <country>Lithuania</country>
    <country>Norway</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Slovakia</country>
    <country>Sweden</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <reference>
    <citation>Henry O, Brzostek J, Czajka H, Leviniene G, Reshetko O, Gasparini R, Pazdiora P, Plesca D, Desole MG, Kevalas R, Gabutti G, Povey M, Innis B. One or two doses of live varicella virus-containing vaccines: Efficacy, persistence of immune responses, and safety six years after administration in healthy children during their second year of life. Vaccine. 2018 Jan 8;36(3):381-387. doi: 10.1016/j.vaccine.2017.11.081. Epub 2017 Dec 7. Erratum in: Vaccine. 2018 Oct 29;36(45):6894.</citation>
    <PMID>29224964</PMID>
  </reference>
  <reference>
    <citation>Prymula R, Bergsaker MR, Esposito S, Gothefors L, Man S, Snegova N, Štefkovičova M, Usonis V, Wysocki J, Douha M, Vassilev V, Nicholson O, Innis BL, Willems P. Protection against varicella with two doses of combined measles-mumps-rubella-varicella vaccine versus one dose of monovalent varicella vaccine: a multicentre, observer-blind, randomised, controlled trial. Lancet. 2014 Apr 12;383(9925):1313-1324. doi: 10.1016/S0140-6736(12)61461-5. Epub 2014 Jan 29. Erratum in: Lancet. 2020 Jan 25;395(10220):272.</citation>
    <PMID>24485548</PMID>
  </reference>
  <reference>
    <citation>Carryn S, Feyssaguet M, Povey M, Di Paolo E. Long-term immunogenicity of measles, mumps and rubella-containing vaccines in healthy young children: A 10-year follow-up. Vaccine. 2019 Aug 23;37(36):5323-5331. doi: 10.1016/j.vaccine.2019.07.049. Epub 2019 Jul 22.</citation>
    <PMID>31345639</PMID>
  </reference>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>September 23, 2005</study_first_submitted>
  <study_first_submitted_qc>September 23, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 27, 2005</study_first_posted>
  <results_first_submitted>June 15, 2017</results_first_submitted>
  <results_first_submitted_qc>August 19, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">September 23, 2019</results_first_posted>
  <last_update_submitted>August 19, 2019</last_update_submitted>
  <last_update_submitted_qc>August 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chickenpox</mesh_term>
    <mesh_term>Herpes Zoster</mesh_term>
    <mesh_term>Rubella</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD for this study will be made available via the Clinical Study Data Request site.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>IPD is available via the Clinical Study Data Request site (click on the link provided below)</ipd_time_frame>
    <ipd_access_criteria>Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.</ipd_access_criteria>
    <ipd_url>https://clinicalstudydatarequest.com</ipd_url>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>100388</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>100388</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>100388</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>100388</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>100388</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>100388</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>MMRV Group</title>
          <description>Subjects in this group received 2 doses of Priorix-Tetra vaccine, administered subcutaneously in the deltoid region of the left arm, one at Day 0 (Visit 1) and the other at Day 42 (Visit 2).</description>
        </group>
        <group group_id="P2">
          <title>OKAH Group</title>
          <description>Subjects in this group received 1 dose of Priorix at Day 0 (Visit 1) and 1 dose of Varilrix at Day 42 (Visit 2). Both vaccines were administered subcutaneously in the deltoid region of the left arm.</description>
        </group>
        <group group_id="P3">
          <title>MMR Group</title>
          <description>Subjects in this group received 2 doses of Priorix, administered subcutaneously in the deltoid region of the left arm, one at Day 0 (Visit 1) and the other at Day 42 (Visit 2).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2489"/>
                <participants group_id="P2" count="2487"/>
                <participants group_id="P3" count="827"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1415"/>
                <participants group_id="P2" count="1415"/>
                <participants group_id="P3" count="468"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1074"/>
                <participants group_id="P2" count="1072"/>
                <participants group_id="P3" count="359"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Others</title>
              <participants_list>
                <participants group_id="P1" count="1064"/>
                <participants group_id="P2" count="1066"/>
                <participants group_id="P3" count="356"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>MMRV Group</title>
          <description>Subjects in this group received 2 doses of Priorix-Tetra vaccine, administered subcutaneously in the deltoid region of the left arm, one at Day 0 (Visit 1) and the other at Day 42 (Visit 2).</description>
        </group>
        <group group_id="B2">
          <title>OKAH Group</title>
          <description>Subjects in this group received 1 dose of Priorix at Day 0 (Visit 1) and 1 dose of Varilrix at Day 42 (Visit 2). Both vaccines were administered subcutaneously in the deltoid region of the left arm.</description>
        </group>
        <group group_id="B3">
          <title>MMR Group</title>
          <description>Subjects in this group received 2 doses of Priorix, administered subcutaneously in the deltoid region of the left arm, one at Day 0 (Visit 1) and the other at Day 42 (Visit 2).</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2489"/>
            <count group_id="B2" value="2487"/>
            <count group_id="B3" value="827"/>
            <count group_id="B4" value="5803"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.3" spread="2.5"/>
                    <measurement group_id="B2" value="14.2" spread="2.5"/>
                    <measurement group_id="B3" value="14.2" spread="2.5"/>
                    <measurement group_id="B4" value="14.2" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1154"/>
                    <measurement group_id="B2" value="1223"/>
                    <measurement group_id="B3" value="401"/>
                    <measurement group_id="B4" value="2778"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1335"/>
                    <measurement group_id="B2" value="1264"/>
                    <measurement group_id="B3" value="426"/>
                    <measurement group_id="B4" value="3025"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Race</title>
              <category_list>
                <category>
                  <title>American hispanic</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Arabic/north african</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>East/south east asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Japanese</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>South asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White/caucasian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2430"/>
                    <measurement group_id="B2" value="2446"/>
                    <measurement group_id="B3" value="818"/>
                    <measurement group_id="B4" value="5694"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Phase A: Number of Subjects With Confirmed Varicella Case</title>
        <description>Confirmed varicella case = A case that met the clinical case definition [an illness with acute onset of diffuse, generalized maculopapulovesicular rash (i.e. spots, papules and/or vesicles) without other apparent cause] at least in the opinion of the investigator and was confirmed by laboratory test [Polymerase Chain Reaction (PCR) (+)] OR a case that met the clinical definition confirmed by the Independent Data Monitoring Committee (IDMC) and was epidemiologically linked [Epi (+)] to a valid index case.</description>
        <time_frame>From 42 days post dose 2 until the end of Phase A</time_frame>
        <population>The analysis was performed on the According-to-Protocol (ATP) Cohort for Efficacy (Phase A), which included all evaluable subjects who had efficacy follow-up starting from 42 days post dose 2.</population>
        <group_list>
          <group group_id="O1">
            <title>MMRV Group</title>
            <description>Subjects in this group received 2 doses of Priorix-Tetra vaccine, administered subcutaneously in the deltoid region of the left arm, one at Day 0 (Visit 1) and the other at Day 42 (Visit 2).</description>
          </group>
          <group group_id="O2">
            <title>OKAH Group</title>
            <description>Subjects in this group received 1 dose of Priorix at Day 0 (Visit 1) and 1 dose of Varilrix at Day 42 (Visit 2). Both vaccines were administered subcutaneously in the deltoid region of the left arm.</description>
          </group>
          <group group_id="O3">
            <title>MMR Group</title>
            <description>Subjects in this group received 2 doses of Priorix, administered subcutaneously in the deltoid region of the left arm, one at Day 0 (Visit 1) and the other at Day 42 (Visit 2).</description>
          </group>
        </group_list>
        <measure>
          <title>Phase A: Number of Subjects With Confirmed Varicella Case</title>
          <description>Confirmed varicella case = A case that met the clinical case definition [an illness with acute onset of diffuse, generalized maculopapulovesicular rash (i.e. spots, papules and/or vesicles) without other apparent cause] at least in the opinion of the investigator and was confirmed by laboratory test [Polymerase Chain Reaction (PCR) (+)] OR a case that met the clinical definition confirmed by the Independent Data Monitoring Committee (IDMC) and was epidemiologically linked [Epi (+)] to a valid index case.</description>
          <population>The analysis was performed on the According-to-Protocol (ATP) Cohort for Efficacy (Phase A), which included all evaluable subjects who had efficacy follow-up starting from 42 days post dose 2.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2279"/>
                <count group_id="O2" value="2263"/>
                <count group_id="O3" value="743"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="243"/>
                    <measurement group_id="O3" value="201"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Vaccine Efficacy (VE) was measured by calculating the relative risk of a confirmed varicella case in a vaccine group compared to a confirmed varicella case in the control group.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>To demonstrate at least 60% VE, with respect to confirmed varicella disease over at least a two-year period of follow-up (beginning 42 days post dose 2) of Priorix-Tetra as compared to Priorix).</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>Regression, Cox</method>
            <param_type>Vaccine Efficacy</param_type>
            <param_value>94.943</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>92.446</ci_lower_limit>
            <ci_upper_limit>96.615</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Vaccine Efficacy (VE) was measured by calculating the relative risk of a confirmed varicella case in a vaccine group compared to a confirmed varicella case in the control group.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>To demonstrate at least 60% VE, with respect to confirmed varicella disease over at least a two-year period of follow-up (beginning 42 days post dose 2) of Varilrix as compared to Priorix).</non_inferiority_desc>
            <p_value>0.1265</p_value>
            <method>Regression, Cox</method>
            <param_type>Vaccine Efficacy</param_type>
            <param_value>65.428</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>57.182</ci_lower_limit>
            <ci_upper_limit>72.086</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase A: Number of Subjects With Moderate or Severe Confirmed Varicella Case</title>
        <description>Confirmed varicella case: A case that met the clinical case definition at least in the opinion of the investigator and was confirmed by laboratory test [PCR (+)] OR a case that met the clinical definition confirmed by the IDMC and was epidemiologically linked [Epi (+)] to a valid index case. Moderately severe disease: 8-15 points; severe disease: ≥ 16 points (scored by IDMC using the modified Vázquez scale).</description>
        <time_frame>From 42 days post dose 2 until the end of Phase A</time_frame>
        <population>The analysis was performed on the ATP Cohort for Efficacy (Phase A), which included all evaluable subjects who had efficacy follow-up starting from 42 days post dose 2.</population>
        <group_list>
          <group group_id="O1">
            <title>MMRV Group</title>
            <description>Subjects in this group received 2 doses of Priorix-Tetra vaccine, administered subcutaneously in the deltoid region of the left arm, one at Day 0 (Visit 1) and the other at Day 42 (Visit 2).</description>
          </group>
          <group group_id="O2">
            <title>OKAH Group</title>
            <description>Subjects in this group received 1 dose of Priorix at Day 0 (Visit 1) and 1 dose of Varilrix at Day 42 (Visit 2). Both vaccines were administered subcutaneously in the deltoid region of the left arm.</description>
          </group>
          <group group_id="O3">
            <title>MMR Group</title>
            <description>Subjects in this group received 2 doses of Priorix, administered subcutaneously in the deltoid region of the left arm, one at Day 0 (Visit 1) and the other at Day 42 (Visit 2).</description>
          </group>
        </group_list>
        <measure>
          <title>Phase A: Number of Subjects With Moderate or Severe Confirmed Varicella Case</title>
          <description>Confirmed varicella case: A case that met the clinical case definition at least in the opinion of the investigator and was confirmed by laboratory test [PCR (+)] OR a case that met the clinical definition confirmed by the IDMC and was epidemiologically linked [Epi (+)] to a valid index case. Moderately severe disease: 8-15 points; severe disease: ≥ 16 points (scored by IDMC using the modified Vázquez scale).</description>
          <population>The analysis was performed on the ATP Cohort for Efficacy (Phase A), which included all evaluable subjects who had efficacy follow-up starting from 42 days post dose 2.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2279"/>
                <count group_id="O2" value="2263"/>
                <count group_id="O3" value="743"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="37"/>
                    <measurement group_id="O3" value="117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>VE was measured by calculating the relative risk of a moderate or severe confirmed varicella case in a vaccine group compared to a moderate or severe confirmed varicella case in the control group.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>To demonstrate at least 60% VE, with respect to confirmed varicella disease over at least a two-year period of follow-up (beginning 42 days post dose 2) of Priorix-Tetra as compared to Priorix).</non_inferiority_desc>
            <p_value>0.0001</p_value>
            <method>Regression, Cox</method>
            <param_type>Vaccine Efficacy</param_type>
            <param_value>99.498</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>97.522</ci_lower_limit>
            <ci_upper_limit>99.898</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>VE was measured by calculating the relative risk of a moderate or severe confirmed varicella case in a vaccine group compared to a moderate or severe confirmed varicella case in the control group.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>To demonstrate at least 60% VE, with respect to confirmed varicella disease over at least a two-year period of follow-up (beginning 42 days post dose 2) of Varilrix as compared to Priorix).</non_inferiority_desc>
            <p_value>0.1265</p_value>
            <method>Regression, Cox</method>
            <param_type>Vaccine Efficacy</param_type>
            <param_value>90.741</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>85.866</ci_lower_limit>
            <ci_upper_limit>93.934</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase A: Number of Subjects With Probable or Confirmed Varicella Case</title>
        <description>Probable or confirmed varicella case = A case that met the clinical case definition (as determined by the IDMC) but was not laboratory confirmed [PCR (‑)] AND was not epidemiologically linked [Epi (‑)] to another probable or confirmed case.</description>
        <time_frame>From 42 days post dose 2 until the end of Phase A</time_frame>
        <population>The analysis was performed on the ATP Cohort for Efficacy (Phase A), which included all evaluable subjects who had efficacy follow-up starting from 42 days post dose 2.</population>
        <group_list>
          <group group_id="O1">
            <title>MMRV Group</title>
            <description>Subjects in this group received 2 doses of Priorix-Tetra vaccine, administered subcutaneously in the deltoid region of the left arm, one at Day 0 (Visit 1) and the other at Day 42 (Visit 2).</description>
          </group>
          <group group_id="O2">
            <title>OKAH Group</title>
            <description>Subjects in this group received 1 dose of Priorix at Day 0 (Visit 1) and 1 dose of Varilrix at Day 42 (Visit 2). Both vaccines were administered subcutaneously in the deltoid region of the left arm.</description>
          </group>
          <group group_id="O3">
            <title>MMR Group</title>
            <description>Subjects in this group received 2 doses of Priorix, administered subcutaneously in the deltoid region of the left arm, one at Day 0 (Visit 1) and the other at Day 42 (Visit 2).</description>
          </group>
        </group_list>
        <measure>
          <title>Phase A: Number of Subjects With Probable or Confirmed Varicella Case</title>
          <description>Probable or confirmed varicella case = A case that met the clinical case definition (as determined by the IDMC) but was not laboratory confirmed [PCR (‑)] AND was not epidemiologically linked [Epi (‑)] to another probable or confirmed case.</description>
          <population>The analysis was performed on the ATP Cohort for Efficacy (Phase A), which included all evaluable subjects who had efficacy follow-up starting from 42 days post dose 2.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2279"/>
                <count group_id="O2" value="2263"/>
                <count group_id="O3" value="743"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="260"/>
                    <measurement group_id="O3" value="209"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>VE was measured by calculating the relative risk of a probable or confirmed varicella case in a vaccine group compared to a probable or confirmed varicella case in the control group.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>To demonstrate at least 60% VE, with respect to confirmed varicella disease over at least a two-year period of follow-up (beginning 42 days post dose 2) of Priorix-Tetra as compared to Priorix).</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>Regression, Cox</method>
            <param_type>Vaccine Efficacy</param_type>
            <param_value>92.487</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>89.927</ci_lower_limit>
            <ci_upper_limit>94.396</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>VE was measured by calculating the relative risk of a probable or confirmed varicella case in a vaccine group compared to a probable or confirmed varicella case in the control group.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>To demonstrate at least 60% VE, with respect to confirmed varicella disease over at least a two-year period of follow-up (beginning 42 days post dose 2) of Varilrix as compared to Priorix).</non_inferiority_desc>
            <p_value>0.1265</p_value>
            <method>Regression, Cox</method>
            <param_type>Vaccine Efficacy</param_type>
            <param_value>64.585</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>57.503</ci_lower_limit>
            <ci_upper_limit>70.486</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase A: Immune Response to Varicella Vaccine With Respect to Anti-Varicella Zoster Virus (Anti-VZV) Antibody Concentrations</title>
        <description>Anti-VZV antibody concentrations are presented as Geometric Mean Concentrations (GMCs), expressed in milliinternational units per milliliter (mIU/mL).</description>
        <time_frame>At Day 0, Day 42, Day 84, Year 1 and Year 2 time points</time_frame>
        <population>The analysis was performed on the ATP Cohort for Immunogenicity, which included all evaluable subjects who had pre-vaccination results available for at least one of the vaccine components.</population>
        <group_list>
          <group group_id="O1">
            <title>MMRV Group</title>
            <description>Subjects in this group received 2 doses of Priorix-Tetra vaccine, administered subcutaneously in the deltoid region of the left arm, one at Day 0 (Visit 1) and the other at Day 42 (Visit 2).</description>
          </group>
          <group group_id="O2">
            <title>OKAH Group</title>
            <description>Subjects in this group received 1 dose of Priorix at Day 0 (Visit 1) and 1 dose of Varilrix at Day 42 (Visit 2). Both vaccines were administered subcutaneously in the deltoid region of the left arm.</description>
          </group>
          <group group_id="O3">
            <title>MMR Group</title>
            <description>Subjects in this group received 2 doses of Priorix, administered subcutaneously in the deltoid region of the left arm, one at Day 0 (Visit 1) and the other at Day 42 (Visit 2).</description>
          </group>
        </group_list>
        <measure>
          <title>Phase A: Immune Response to Varicella Vaccine With Respect to Anti-Varicella Zoster Virus (Anti-VZV) Antibody Concentrations</title>
          <description>Anti-VZV antibody concentrations are presented as Geometric Mean Concentrations (GMCs), expressed in milliinternational units per milliliter (mIU/mL).</description>
          <population>The analysis was performed on the ATP Cohort for Immunogenicity, which included all evaluable subjects who had pre-vaccination results available for at least one of the vaccine components.</population>
          <units>mIU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2245"/>
                <count group_id="O2" value="2245"/>
                <count group_id="O3" value="742"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-VZV, Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2245"/>
                    <count group_id="O2" value="2245"/>
                    <count group_id="O3" value="742"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.8" lower_limit="12.6" upper_limit="12.9"/>
                    <measurement group_id="O2" value="12.7" lower_limit="12.6" upper_limit="12.8"/>
                    <measurement group_id="O3" value="12.6" lower_limit="12.5" upper_limit="12.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-VZV, Day 42</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="690"/>
                    <count group_id="O2" value="697"/>
                    <count group_id="O3" value="231"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116.1" lower_limit="108.3" upper_limit="124.5"/>
                    <measurement group_id="O2" value="13.5" lower_limit="13.0" upper_limit="14.1"/>
                    <measurement group_id="O3" value="13.1" lower_limit="12.5" upper_limit="13.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-VZV, Day 84</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2241"/>
                    <count group_id="O2" value="2234"/>
                    <count group_id="O3" value="740"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1833.3" lower_limit="1767.8" upper_limit="1901.3"/>
                    <measurement group_id="O2" value="98.1" lower_limit="94.2" upper_limit="102.3"/>
                    <measurement group_id="O3" value="14.7" lower_limit="13.9" upper_limit="15.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-VZV, Year 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2066"/>
                    <count group_id="O2" value="2053"/>
                    <count group_id="O3" value="673"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="365.1" lower_limit="349.0" upper_limit="381.9"/>
                    <measurement group_id="O2" value="145.2" lower_limit="137.0" upper_limit="153.8"/>
                    <measurement group_id="O3" value="20.3" lower_limit="18.2" upper_limit="22.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-VZV, Year 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1924"/>
                    <count group_id="O2" value="1916"/>
                    <count group_id="O3" value="635"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="414.6" lower_limit="392.1" upper_limit="438.5"/>
                    <measurement group_id="O2" value="170.6" lower_limit="158.1" upper_limit="184.1"/>
                    <measurement group_id="O3" value="36.9" lower_limit="31.6" upper_limit="43.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase A: Number of Subjects With Seroconversion/Seroresponse to VZV</title>
        <description>Seronegative (S-) = Subjects with antibody concentration less than (&lt;) 25 mIU/mL prior to vaccination. Seropositive (S+) = Subjects with antibody concentration greater than or equal to (≥) 25 mIU/mL prior to vaccination. Seroconversion was defined as the appearance of antibodies (i.e. titer greater than or equal to the cut-off value) in the serum of subjects seronegative before vaccination.</description>
        <time_frame>At Day 0, Day 42, Day 84, Year 1 and Year 2 time points</time_frame>
        <population>The analysis was performed on the ATP Cohort for Immunogenicity, which included all evaluable subjects who had pre-vaccination results available for at least one of the vaccine components.</population>
        <group_list>
          <group group_id="O1">
            <title>MMRV Group</title>
            <description>Subjects in this group received 2 doses of Priorix-Tetra vaccine, administered subcutaneously in the deltoid region of the left arm, one at Day 0 (Visit 1) and the other at Day 42 (Visit 2).</description>
          </group>
          <group group_id="O2">
            <title>OKAH Group</title>
            <description>Subjects in this group received 1 dose of Priorix at Day 0 (Visit 1) and 1 dose of Varilrix at Day 42 (Visit 2). Both vaccines were administered subcutaneously in the deltoid region of the left arm.</description>
          </group>
          <group group_id="O3">
            <title>MMR Group</title>
            <description>Subjects in this group received 2 doses of Priorix, administered subcutaneously in the deltoid region of the left arm, one at Day 0 (Visit 1) and the other at Day 42 (Visit 2).</description>
          </group>
        </group_list>
        <measure>
          <title>Phase A: Number of Subjects With Seroconversion/Seroresponse to VZV</title>
          <description>Seronegative (S-) = Subjects with antibody concentration less than (&lt;) 25 mIU/mL prior to vaccination. Seropositive (S+) = Subjects with antibody concentration greater than or equal to (≥) 25 mIU/mL prior to vaccination. Seroconversion was defined as the appearance of antibodies (i.e. titer greater than or equal to the cut-off value) in the serum of subjects seronegative before vaccination.</description>
          <population>The analysis was performed on the ATP Cohort for Immunogenicity, which included all evaluable subjects who had pre-vaccination results available for at least one of the vaccine components.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2245"/>
                <count group_id="O2" value="2245"/>
                <count group_id="O3" value="742"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-VZV, Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2245"/>
                    <count group_id="O2" value="2245"/>
                    <count group_id="O3" value="742"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-VZV, Day 42</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="690"/>
                    <count group_id="O2" value="697"/>
                    <count group_id="O3" value="231"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="661"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-VZV, Day 84</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2241"/>
                    <count group_id="O2" value="2234"/>
                    <count group_id="O3" value="740"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2236"/>
                    <measurement group_id="O2" value="2123"/>
                    <measurement group_id="O3" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-VZV, Year 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2066"/>
                    <count group_id="O2" value="2053"/>
                    <count group_id="O3" value="673"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2056"/>
                    <measurement group_id="O2" value="1968"/>
                    <measurement group_id="O3" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-VZV, Year 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1924"/>
                    <count group_id="O2" value="1916"/>
                    <count group_id="O3" value="635"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1913"/>
                    <measurement group_id="O2" value="1776"/>
                    <measurement group_id="O3" value="170"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase A: Immune Response to Measles With Respect to Anti-measles Antibody Concentrations in a Subset of Subjects</title>
        <description>Anti-measles antibody concentrations are presented as Geometric Mean Concentrations (GMCs), expressed in milliinternational units per milliliter (mIU/mL).</description>
        <time_frame>At Day 0, Day 42, Day 84, Year 1 and Year 2 time points</time_frame>
        <population>The analysis was performed on the ATP Cohort for Immunogenicity, which included all evaluable subjects who had pre-vaccination results available for at least one of the vaccine components.</population>
        <group_list>
          <group group_id="O1">
            <title>MMRV Group</title>
            <description>Subjects in this group received 2 doses of Priorix-Tetra vaccine, administered subcutaneously in the deltoid region of the left arm, one at Day 0 (Visit 1) and the other at Day 42 (Visit 2).</description>
          </group>
          <group group_id="O2">
            <title>OKAH Group</title>
            <description>Subjects in this group received 1 dose of Priorix at Day 0 (Visit 1) and 1 dose of Varilrix at Day 42 (Visit 2). Both vaccines were administered subcutaneously in the deltoid region of the left arm.</description>
          </group>
          <group group_id="O3">
            <title>MMR Group</title>
            <description>Subjects in this group received 2 doses of Priorix, administered subcutaneously in the deltoid region of the left arm, one at Day 0 (Visit 1) and the other at Day 42 (Visit 2).</description>
          </group>
        </group_list>
        <measure>
          <title>Phase A: Immune Response to Measles With Respect to Anti-measles Antibody Concentrations in a Subset of Subjects</title>
          <description>Anti-measles antibody concentrations are presented as Geometric Mean Concentrations (GMCs), expressed in milliinternational units per milliliter (mIU/mL).</description>
          <population>The analysis was performed on the ATP Cohort for Immunogenicity, which included all evaluable subjects who had pre-vaccination results available for at least one of the vaccine components.</population>
          <units>mIU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="704"/>
                <count group_id="O2" value="713"/>
                <count group_id="O3" value="232"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-measles, Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="704"/>
                    <count group_id="O2" value="713"/>
                    <count group_id="O3" value="232"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.7" lower_limit="74.6" upper_limit="76.8"/>
                    <measurement group_id="O2" value="77.9" lower_limit="75.6" upper_limit="80.3"/>
                    <measurement group_id="O3" value="77.9" lower_limit="73.9" upper_limit="82.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-measles, Day 42</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="691"/>
                    <count group_id="O2" value="698"/>
                    <count group_id="O3" value="230"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3961.0" lower_limit="3719.7" upper_limit="4217.9"/>
                    <measurement group_id="O2" value="2602.7" lower_limit="2429.6" upper_limit="2788.1"/>
                    <measurement group_id="O3" value="2817.4" lower_limit="2506.3" upper_limit="3167.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-measles, Day 84</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="704"/>
                    <count group_id="O2" value="712"/>
                    <count group_id="O3" value="231"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5809.6" lower_limit="5544.5" upper_limit="6087.3"/>
                    <measurement group_id="O2" value="3438.1" lower_limit="3210.9" upper_limit="3681.5"/>
                    <measurement group_id="O3" value="3695.0" lower_limit="3318.2" upper_limit="4114.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-measles, Year 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="630"/>
                    <count group_id="O2" value="630"/>
                    <count group_id="O3" value="200"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4993.7" lower_limit="4714.7" upper_limit="5289.2"/>
                    <measurement group_id="O2" value="2856.8" lower_limit="2658.6" upper_limit="3069.7"/>
                    <measurement group_id="O3" value="2885.7" lower_limit="2520.7" upper_limit="3303.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-measles, Year 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="589"/>
                    <count group_id="O2" value="593"/>
                    <count group_id="O3" value="187"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4709.6" lower_limit="4407.1" upper_limit="5033.0"/>
                    <measurement group_id="O2" value="2624.5" lower_limit="2423.6" upper_limit="2842.2"/>
                    <measurement group_id="O3" value="2677.9" lower_limit="2302.5" upper_limit="3114.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase A: Number of Subjects With Seroconversion/Seroresponse to Measles in a Subset of Subjects</title>
        <description>Seronegative (S-) = Subjects with antibody concentration &lt; 150 mIU/mL prior to vaccination. Seropositive (S+) = Subjects with antibody concentration ≥ 150 mIU/mL prior to vaccination. Seroconversion was defined as the appearance of antibodies (i.e. titer greater than or equal to the cut-off value) in the serum of subjects seronegative before vaccination.</description>
        <time_frame>At Day 0, Day 42, Day 84, Year 1 and Year 2 time points</time_frame>
        <population>The analysis was performed on the ATP Cohort for Immunogenicity, which included all evaluable subjects who had pre-vaccination results available for at least one of the vaccine components.</population>
        <group_list>
          <group group_id="O1">
            <title>MMRV Group</title>
            <description>Subjects in this group received 2 doses of Priorix-Tetra vaccine, administered subcutaneously in the deltoid region of the left arm, one at Day 0 (Visit 1) and the other at Day 42 (Visit 2).</description>
          </group>
          <group group_id="O2">
            <title>OKAH Group</title>
            <description>Subjects in this group received 1 dose of Priorix at Day 0 (Visit 1) and 1 dose of Varilrix at Day 42 (Visit 2). Both vaccines were administered subcutaneously in the deltoid region of the left arm.</description>
          </group>
          <group group_id="O3">
            <title>MMR Group</title>
            <description>Subjects in this group received 2 doses of Priorix, administered subcutaneously in the deltoid region of the left arm, one at Day 0 (Visit 1) and the other at Day 42 (Visit 2).</description>
          </group>
        </group_list>
        <measure>
          <title>Phase A: Number of Subjects With Seroconversion/Seroresponse to Measles in a Subset of Subjects</title>
          <description>Seronegative (S-) = Subjects with antibody concentration &lt; 150 mIU/mL prior to vaccination. Seropositive (S+) = Subjects with antibody concentration ≥ 150 mIU/mL prior to vaccination. Seroconversion was defined as the appearance of antibodies (i.e. titer greater than or equal to the cut-off value) in the serum of subjects seronegative before vaccination.</description>
          <population>The analysis was performed on the ATP Cohort for Immunogenicity, which included all evaluable subjects who had pre-vaccination results available for at least one of the vaccine components.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="704"/>
                <count group_id="O2" value="713"/>
                <count group_id="O3" value="232"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-measles, Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="704"/>
                    <count group_id="O2" value="713"/>
                    <count group_id="O3" value="232"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-measles, Day 42</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="691"/>
                    <count group_id="O2" value="698"/>
                    <count group_id="O3" value="230"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="676"/>
                    <measurement group_id="O2" value="682"/>
                    <measurement group_id="O3" value="225"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-measles, Day 84</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="704"/>
                    <count group_id="O2" value="712"/>
                    <count group_id="O3" value="231"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="703"/>
                    <measurement group_id="O2" value="702"/>
                    <measurement group_id="O3" value="230"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-measles, Year 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="630"/>
                    <count group_id="O2" value="630"/>
                    <count group_id="O3" value="200"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="628"/>
                    <measurement group_id="O2" value="621"/>
                    <measurement group_id="O3" value="198"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-measles, Year 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="589"/>
                    <count group_id="O2" value="593"/>
                    <count group_id="O3" value="187"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="584"/>
                    <measurement group_id="O2" value="583"/>
                    <measurement group_id="O3" value="183"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase A: Immune Response to Mumps With Respect to Anti-mumps Antibody Concentrations in a Subset of Subjects</title>
        <description>Anti-mumps antibody concentrations are presented as Geometric Mean Concentrations (GMCs), expressed in units per milliliter (U/mL).</description>
        <time_frame>At Day 0, Day 42, Day 84, Year 1 and Year 2 time points</time_frame>
        <population>The analysis was performed on the ATP Cohort for Immunogenicity, which included all evaluable subjects who had pre-vaccination results available for at least one of the vaccine components.</population>
        <group_list>
          <group group_id="O1">
            <title>MMRV Group</title>
            <description>Subjects in this group received 2 doses of Priorix-Tetra vaccine, administered subcutaneously in the deltoid region of the left arm, one at Day 0 (Visit 1) and the other at Day 42 (Visit 2).</description>
          </group>
          <group group_id="O2">
            <title>OKAH Group</title>
            <description>Subjects in this group received 1 dose of Priorix at Day 0 (Visit 1) and 1 dose of Varilrix at Day 42 (Visit 2). Both vaccines were administered subcutaneously in the deltoid region of the left arm.</description>
          </group>
          <group group_id="O3">
            <title>MMR Group</title>
            <description>Subjects in this group received 2 doses of Priorix, administered subcutaneously in the deltoid region of the left arm, one at Day 0 (Visit 1) and the other at Day 42 (Visit 2).</description>
          </group>
        </group_list>
        <measure>
          <title>Phase A: Immune Response to Mumps With Respect to Anti-mumps Antibody Concentrations in a Subset of Subjects</title>
          <description>Anti-mumps antibody concentrations are presented as Geometric Mean Concentrations (GMCs), expressed in units per milliliter (U/mL).</description>
          <population>The analysis was performed on the ATP Cohort for Immunogenicity, which included all evaluable subjects who had pre-vaccination results available for at least one of the vaccine components.</population>
          <units>U/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="704"/>
                <count group_id="O2" value="712"/>
                <count group_id="O3" value="232"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-mumps, Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="704"/>
                    <count group_id="O2" value="712"/>
                    <count group_id="O3" value="232"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="117.5" lower_limit="115.4" upper_limit="119.7"/>
                    <measurement group_id="O2" value="119.1" lower_limit="116.2" upper_limit="122.2"/>
                    <measurement group_id="O3" value="118.1" lower_limit="114.4" upper_limit="122.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-mumps, Day 42</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="667"/>
                    <count group_id="O2" value="670"/>
                    <count group_id="O3" value="225"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="896.6" lower_limit="827.0" upper_limit="972.0"/>
                    <measurement group_id="O2" value="925.0" lower_limit="859.4" upper_limit="995.7"/>
                    <measurement group_id="O3" value="945.2" lower_limit="839.0" upper_limit="1064.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-mumps, Day 84</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="698"/>
                    <count group_id="O2" value="701"/>
                    <count group_id="O3" value="225"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1496.8" lower_limit="1407.7" upper_limit="1591.7"/>
                    <measurement group_id="O2" value="759.8" lower_limit="705.5" upper_limit="818.3"/>
                    <measurement group_id="O3" value="1547.9" lower_limit="1408.0" upper_limit="1701.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-mumps, Year 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="624"/>
                    <count group_id="O2" value="622"/>
                    <count group_id="O3" value="196"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1008.6" lower_limit="928.8" upper_limit="1095.2"/>
                    <measurement group_id="O2" value="875.9" lower_limit="805.8" upper_limit="952.2"/>
                    <measurement group_id="O3" value="1089.6" lower_limit="944.0" upper_limit="1257.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-mumps, Year 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="582"/>
                    <count group_id="O2" value="587"/>
                    <count group_id="O3" value="187"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1050.6" lower_limit="957.5" upper_limit="1152.7"/>
                    <measurement group_id="O2" value="882.0" lower_limit="805.6" upper_limit="965.6"/>
                    <measurement group_id="O3" value="989.4" lower_limit="848.3" upper_limit="1153.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase A: Number of Subjects With Seroconversion/Seroresponse to Mumps in a Subset of Subjects</title>
        <description>Seronegative (S-) = Subjects with antibody concentration &lt; 231 U/mL prior to vaccination. Seropositive (S+) = Subjects with antibody concentration ≥ 231 U/mL prior to vaccination. Seroconversion was defined as the appearance of antibodies (i.e. titer greater than or equal to the cut-off value) in the serum of subjects seronegative before vaccination.</description>
        <time_frame>At Day 0, Day 42, Day 84, Year 1 and Year 2 time points</time_frame>
        <population>The analysis was performed on the ATP Cohort for Immunogenicity, which included all evaluable subjects who had pre-vaccination results available for at least one of the vaccine components.</population>
        <group_list>
          <group group_id="O1">
            <title>MMRV Group</title>
            <description>Subjects in this group received 2 doses of Priorix-Tetra vaccine, administered subcutaneously in the deltoid region of the left arm, one at Day 0 (Visit 1) and the other at Day 42 (Visit 2).</description>
          </group>
          <group group_id="O2">
            <title>OKAH Group</title>
            <description>Subjects in this group received 1 dose of Priorix at Day 0 (Visit 1) and 1 dose of Varilrix at Day 42 (Visit 2). Both vaccines were administered subcutaneously in the deltoid region of the left arm.</description>
          </group>
          <group group_id="O3">
            <title>MMR Group</title>
            <description>Subjects in this group received 2 doses of Priorix, administered subcutaneously in the deltoid region of the left arm, one at Day 0 (Visit 1) and the other at Day 42 (Visit 2).</description>
          </group>
        </group_list>
        <measure>
          <title>Phase A: Number of Subjects With Seroconversion/Seroresponse to Mumps in a Subset of Subjects</title>
          <description>Seronegative (S-) = Subjects with antibody concentration &lt; 231 U/mL prior to vaccination. Seropositive (S+) = Subjects with antibody concentration ≥ 231 U/mL prior to vaccination. Seroconversion was defined as the appearance of antibodies (i.e. titer greater than or equal to the cut-off value) in the serum of subjects seronegative before vaccination.</description>
          <population>The analysis was performed on the ATP Cohort for Immunogenicity, which included all evaluable subjects who had pre-vaccination results available for at least one of the vaccine components.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="704"/>
                <count group_id="O2" value="712"/>
                <count group_id="O3" value="232"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-mumps, Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="704"/>
                    <count group_id="O2" value="712"/>
                    <count group_id="O3" value="232"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-mumps, Day 42</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="667"/>
                    <count group_id="O2" value="670"/>
                    <count group_id="O3" value="225"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="584"/>
                    <measurement group_id="O2" value="613"/>
                    <measurement group_id="O3" value="208"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-mumps, Day 84</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="698"/>
                    <count group_id="O2" value="701"/>
                    <count group_id="O3" value="225"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="683"/>
                    <measurement group_id="O2" value="608"/>
                    <measurement group_id="O3" value="225"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-mumps, Year 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="624"/>
                    <count group_id="O2" value="622"/>
                    <count group_id="O3" value="196"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="569"/>
                    <measurement group_id="O2" value="554"/>
                    <measurement group_id="O3" value="182"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-mumps, Year 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="582"/>
                    <count group_id="O2" value="587"/>
                    <count group_id="O3" value="187"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="527"/>
                    <measurement group_id="O2" value="520"/>
                    <measurement group_id="O3" value="171"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase A: Immune Response to Rubella With Respect to Anti-rubella Antibody Concentrations in a Subset of Subjects</title>
        <description>Anti-rubella antibody concentrations are presented as Geometric Mean Concentrations (GMCs), expressed in International Units per milliliter (IU/mL).</description>
        <time_frame>At Day 0, Day 42, Day 84, Year 1 and Year 2 time points</time_frame>
        <population>The analysis was performed on the ATP Cohort for Immunogenicity, which included all evaluable subjects who had pre-vaccination results available for at least one of the vaccine components.</population>
        <group_list>
          <group group_id="O1">
            <title>MMRV Group</title>
            <description>Subjects in this group received 2 doses of Priorix-Tetra vaccine, administered subcutaneously in the deltoid region of the left arm, one at Day 0 (Visit 1) and the other at Day 42 (Visit 2).</description>
          </group>
          <group group_id="O2">
            <title>OKAH Group</title>
            <description>Subjects in this group received 1 dose of Priorix at Day 0 (Visit 1) and 1 dose of Varilrix at Day 42 (Visit 2). Both vaccines were administered subcutaneously in the deltoid region of the left arm.</description>
          </group>
          <group group_id="O3">
            <title>MMR Group</title>
            <description>Subjects in this group received 2 doses of Priorix, administered subcutaneously in the deltoid region of the left arm, one at Day 0 (Visit 1) and the other at Day 42 (Visit 2).</description>
          </group>
        </group_list>
        <measure>
          <title>Phase A: Immune Response to Rubella With Respect to Anti-rubella Antibody Concentrations in a Subset of Subjects</title>
          <description>Anti-rubella antibody concentrations are presented as Geometric Mean Concentrations (GMCs), expressed in International Units per milliliter (IU/mL).</description>
          <population>The analysis was performed on the ATP Cohort for Immunogenicity, which included all evaluable subjects who had pre-vaccination results available for at least one of the vaccine components.</population>
          <units>IU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="704"/>
                <count group_id="O2" value="713"/>
                <count group_id="O3" value="232"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-rubella, Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="704"/>
                    <count group_id="O2" value="713"/>
                    <count group_id="O3" value="232"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" lower_limit="2.0" upper_limit="2.1"/>
                    <measurement group_id="O2" value="2.0" lower_limit="2.0" upper_limit="2.1"/>
                    <measurement group_id="O3" value="2.1" lower_limit="2.0" upper_limit="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-rubella, Day 42</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="692"/>
                    <count group_id="O2" value="698"/>
                    <count group_id="O3" value="230"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.6" lower_limit="54.2" upper_limit="61.2"/>
                    <measurement group_id="O2" value="74.0" lower_limit="69.9" upper_limit="78.3"/>
                    <measurement group_id="O3" value="71.0" lower_limit="64.8" upper_limit="77.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-rubella, Day 84</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="704"/>
                    <count group_id="O2" value="712"/>
                    <count group_id="O3" value="231"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104.7" lower_limit="99.8" upper_limit="109.8"/>
                    <measurement group_id="O2" value="122.1" lower_limit="116.2" upper_limit="128.2"/>
                    <measurement group_id="O3" value="111.9" lower_limit="103.5" upper_limit="120.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-rubella, Year 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="630"/>
                    <count group_id="O2" value="630"/>
                    <count group_id="O3" value="200"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.7" lower_limit="83.9" upper_limit="93.8"/>
                    <measurement group_id="O2" value="103.7" lower_limit="97.8" upper_limit="110.0"/>
                    <measurement group_id="O3" value="98.0" lower_limit="88.7" upper_limit="108.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-rubella, Year 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="589"/>
                    <count group_id="O2" value="593"/>
                    <count group_id="O3" value="187"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.8" lower_limit="67.5" upper_limit="76.4"/>
                    <measurement group_id="O2" value="79.1" lower_limit="74.2" upper_limit="84.3"/>
                    <measurement group_id="O3" value="71.8" lower_limit="64.0" upper_limit="80.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase A: Number of Subjects With a Seroconversion/Seroresponse to Rubella in a Subset of Subjects</title>
        <description>Seronegative (S-) = Subjects with antibody concentration &lt; 4 IU/mL prior to vaccination. Seropositive (S+) = Subjects with antibody concentration ≥ 4 IU/mL prior to vaccination. Seroconversion was defined as the appearance of antibodies (i.e. titer greater than or equal to the cut-off value) in the serum of subjects seronegative before vaccination.</description>
        <time_frame>At Day 0, Day 42, Day 84, Year 1 and Year 2 time points</time_frame>
        <population>The analysis was performed on the ATP Cohort for Immunogenicity, which included all evaluable subjects who had pre-vaccination results available for at least one of the vaccine components.</population>
        <group_list>
          <group group_id="O1">
            <title>MMRV Group</title>
            <description>Subjects in this group received 2 doses of Priorix-Tetra vaccine, administered subcutaneously in the deltoid region of the left arm, one at Day 0 (Visit 1) and the other at Day 42 (Visit 2).</description>
          </group>
          <group group_id="O2">
            <title>OKAH Group</title>
            <description>Subjects in this group received 1 dose of Priorix at Day 0 (Visit 1) and 1 dose of Varilrix at Day 42 (Visit 2). Both vaccines were administered subcutaneously in the deltoid region of the left arm.</description>
          </group>
          <group group_id="O3">
            <title>MMR Group</title>
            <description>Subjects in this group received 2 doses of Priorix, administered subcutaneously in the deltoid region of the left arm, one at Day 0 (Visit 1) and the other at Day 42 (Visit 2).</description>
          </group>
        </group_list>
        <measure>
          <title>Phase A: Number of Subjects With a Seroconversion/Seroresponse to Rubella in a Subset of Subjects</title>
          <description>Seronegative (S-) = Subjects with antibody concentration &lt; 4 IU/mL prior to vaccination. Seropositive (S+) = Subjects with antibody concentration ≥ 4 IU/mL prior to vaccination. Seroconversion was defined as the appearance of antibodies (i.e. titer greater than or equal to the cut-off value) in the serum of subjects seronegative before vaccination.</description>
          <population>The analysis was performed on the ATP Cohort for Immunogenicity, which included all evaluable subjects who had pre-vaccination results available for at least one of the vaccine components.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="704"/>
                <count group_id="O2" value="713"/>
                <count group_id="O3" value="232"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-rubella, Day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="704"/>
                    <count group_id="O2" value="713"/>
                    <count group_id="O3" value="232"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-rubella, Day 42</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="692"/>
                    <count group_id="O2" value="698"/>
                    <count group_id="O3" value="230"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="688"/>
                    <measurement group_id="O2" value="693"/>
                    <measurement group_id="O3" value="230"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-rubella, Day 84</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="704"/>
                    <count group_id="O2" value="712"/>
                    <count group_id="O3" value="231"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="704"/>
                    <measurement group_id="O2" value="710"/>
                    <measurement group_id="O3" value="231"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-rubella, Year 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="630"/>
                    <count group_id="O2" value="630"/>
                    <count group_id="O3" value="200"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="630"/>
                    <measurement group_id="O2" value="628"/>
                    <measurement group_id="O3" value="200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-rubella, Year 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="589"/>
                    <count group_id="O2" value="593"/>
                    <count group_id="O3" value="187"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="589"/>
                    <measurement group_id="O2" value="590"/>
                    <measurement group_id="O3" value="186"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase A: Number of Subjects With Confirmed Cases of Herpes Zoster</title>
        <description>The number of subjects with confirmed cases of herpes zoster is reported.</description>
        <time_frame>From Day 0 until the end of Phase A (Year 2)</time_frame>
        <population>The analysis was performed on the Total Vaccinated Cohort, which included all vaccinated subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>MMRV Group</title>
            <description>Subjects in this group received 2 doses of Priorix-Tetra vaccine, administered subcutaneously in the deltoid region of the left arm, one at Day 0 (Visit 1) and the other at Day 42 (Visit 2).</description>
          </group>
          <group group_id="O2">
            <title>OKAH Group</title>
            <description>Subjects in this group received 1 dose of Priorix at Day 0 (Visit 1) and 1 dose of Varilrix at Day 42 (Visit 2). Both vaccines were administered subcutaneously in the deltoid region of the left arm.</description>
          </group>
          <group group_id="O3">
            <title>MMR Group</title>
            <description>Subjects in this group received 2 doses of Priorix, administered subcutaneously in the deltoid region of the left arm, one at Day 0 (Visit 1) and the other at Day 42 (Visit 2).</description>
          </group>
        </group_list>
        <measure>
          <title>Phase A: Number of Subjects With Confirmed Cases of Herpes Zoster</title>
          <description>The number of subjects with confirmed cases of herpes zoster is reported.</description>
          <population>The analysis was performed on the Total Vaccinated Cohort, which included all vaccinated subjects.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="807"/>
                <count group_id="O2" value="812"/>
                <count group_id="O3" value="268"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase A: Number of Subjects Reporting Fever</title>
        <description>All fever = Occurrence of any fever (measured rectally) regardless of its intensity grade or relationship to vaccination. Related = fever (measured rectally) assessed by the investigator to be causally related to the study vaccination. Medical Advice = seek for medical advice.</description>
        <time_frame>Within 43 days (Day 0-42) post-vaccination period following each dose</time_frame>
        <population>The analysis was performed on a subset of the Total Vaccinated Cohort. The subset of subjects was identified as 200 subjects from each country. Depending on the country, this subset was stipulated to be either the first 200 subjects enrolled irrespective of the study center or 200 subjects enrolled at selected centers.</population>
        <group_list>
          <group group_id="O1">
            <title>MMRV Group</title>
            <description>Subjects in this group received 2 doses of Priorix-Tetra vaccine, administered subcutaneously in the deltoid region of the left arm, one at Day 0 (Visit 1) and the other at Day 42 (Visit 2).</description>
          </group>
          <group group_id="O2">
            <title>OKAH Group</title>
            <description>Subjects in this group received 1 dose of Priorix at Day 0 (Visit 1) and 1 dose of Varilrix at Day 42 (Visit 2). Both vaccines were administered subcutaneously in the deltoid region of the left arm.</description>
          </group>
          <group group_id="O3">
            <title>MMR Group</title>
            <description>Subjects in this group received 2 doses of Priorix, administered subcutaneously in the deltoid region of the left arm, one at Day 0 (Visit 1) and the other at Day 42 (Visit 2).</description>
          </group>
        </group_list>
        <measure>
          <title>Phase A: Number of Subjects Reporting Fever</title>
          <description>All fever = Occurrence of any fever (measured rectally) regardless of its intensity grade or relationship to vaccination. Related = fever (measured rectally) assessed by the investigator to be causally related to the study vaccination. Medical Advice = seek for medical advice.</description>
          <population>The analysis was performed on a subset of the Total Vaccinated Cohort. The subset of subjects was identified as 200 subjects from each country. Depending on the country, this subset was stipulated to be either the first 200 subjects enrolled irrespective of the study center or 200 subjects enrolled at selected centers.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="784"/>
                <count group_id="O2" value="795"/>
                <count group_id="O3" value="256"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All Fever, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="784"/>
                    <count group_id="O2" value="795"/>
                    <count group_id="O3" value="256"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="503"/>
                    <measurement group_id="O2" value="439"/>
                    <measurement group_id="O3" value="132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Fever, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="784"/>
                    <count group_id="O2" value="795"/>
                    <count group_id="O3" value="256"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="332"/>
                    <measurement group_id="O2" value="240"/>
                    <measurement group_id="O3" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Fever ≥ 38°C, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="784"/>
                    <count group_id="O2" value="795"/>
                    <count group_id="O3" value="256"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="332"/>
                    <measurement group_id="O2" value="240"/>
                    <measurement group_id="O3" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Fever &gt; 38.5°C, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="784"/>
                    <count group_id="O2" value="795"/>
                    <count group_id="O3" value="256"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="222"/>
                    <measurement group_id="O2" value="147"/>
                    <measurement group_id="O3" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Fever &gt; 39°C, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="784"/>
                    <count group_id="O2" value="795"/>
                    <count group_id="O3" value="256"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="141"/>
                    <measurement group_id="O2" value="90"/>
                    <measurement group_id="O3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Fever &gt; 39.5°C, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="784"/>
                    <count group_id="O2" value="795"/>
                    <count group_id="O3" value="256"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71"/>
                    <measurement group_id="O2" value="48"/>
                    <measurement group_id="O3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Fever &gt; 40°C, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="784"/>
                    <count group_id="O2" value="795"/>
                    <count group_id="O3" value="256"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever ≥ 38°C, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="784"/>
                    <count group_id="O2" value="795"/>
                    <count group_id="O3" value="256"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="503"/>
                    <measurement group_id="O2" value="439"/>
                    <measurement group_id="O3" value="132"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever &gt; 38.5°C, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="784"/>
                    <count group_id="O2" value="795"/>
                    <count group_id="O3" value="256"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="359"/>
                    <measurement group_id="O2" value="297"/>
                    <measurement group_id="O3" value="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever &gt; 39°C, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="784"/>
                    <count group_id="O2" value="795"/>
                    <count group_id="O3" value="256"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="249"/>
                    <measurement group_id="O2" value="191"/>
                    <measurement group_id="O3" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever &gt; 39.5°C, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="784"/>
                    <count group_id="O2" value="795"/>
                    <count group_id="O3" value="256"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="139"/>
                    <measurement group_id="O2" value="100"/>
                    <measurement group_id="O3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever &gt; 40°C, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="784"/>
                    <count group_id="O2" value="795"/>
                    <count group_id="O3" value="256"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="43"/>
                    <measurement group_id="O3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever Medical Advice, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="784"/>
                    <count group_id="O2" value="795"/>
                    <count group_id="O3" value="256"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="203"/>
                    <measurement group_id="O2" value="177"/>
                    <measurement group_id="O3" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All Fever, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="758"/>
                    <count group_id="O2" value="773"/>
                    <count group_id="O3" value="247"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="303"/>
                    <measurement group_id="O2" value="313"/>
                    <measurement group_id="O3" value="103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Fever, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="758"/>
                    <count group_id="O2" value="773"/>
                    <count group_id="O3" value="247"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="136"/>
                    <measurement group_id="O2" value="144"/>
                    <measurement group_id="O3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Fever ≥ 38°C, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="758"/>
                    <count group_id="O2" value="773"/>
                    <count group_id="O3" value="247"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="136"/>
                    <measurement group_id="O2" value="144"/>
                    <measurement group_id="O3" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Fever &gt; 38.5°C, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="758"/>
                    <count group_id="O2" value="773"/>
                    <count group_id="O3" value="247"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78"/>
                    <measurement group_id="O2" value="88"/>
                    <measurement group_id="O3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Fever &gt; 39°C, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="758"/>
                    <count group_id="O2" value="773"/>
                    <count group_id="O3" value="247"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="54"/>
                    <measurement group_id="O3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Fever &gt; 39.5°C, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="758"/>
                    <count group_id="O2" value="773"/>
                    <count group_id="O3" value="247"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="32"/>
                    <measurement group_id="O3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Fever &gt; 40°C, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="758"/>
                    <count group_id="O2" value="773"/>
                    <count group_id="O3" value="247"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever ≥ 38°C, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="758"/>
                    <count group_id="O2" value="773"/>
                    <count group_id="O3" value="247"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="303"/>
                    <measurement group_id="O2" value="313"/>
                    <measurement group_id="O3" value="103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever &gt; 38.5°C, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="758"/>
                    <count group_id="O2" value="773"/>
                    <count group_id="O3" value="247"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="212"/>
                    <measurement group_id="O2" value="205"/>
                    <measurement group_id="O3" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever &gt; 39°C, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="758"/>
                    <count group_id="O2" value="773"/>
                    <count group_id="O3" value="247"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="136"/>
                    <measurement group_id="O2" value="132"/>
                    <measurement group_id="O3" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever &gt; 39.5°C, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="758"/>
                    <count group_id="O2" value="773"/>
                    <count group_id="O3" value="247"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66"/>
                    <measurement group_id="O2" value="74"/>
                    <measurement group_id="O3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever &gt; 40°C, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="758"/>
                    <count group_id="O2" value="773"/>
                    <count group_id="O3" value="247"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever Medical Advice, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="758"/>
                    <count group_id="O2" value="773"/>
                    <count group_id="O3" value="247"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112"/>
                    <measurement group_id="O2" value="119"/>
                    <measurement group_id="O3" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase A: Number of Subjects Reporting Fever</title>
        <description>All fever = Occurrence of any fever (measured rectally) regardless of its intensity grade or relationship to vaccination. Related fever = fever (measured rectally) assessed by the investigator to be causally related to the study vaccination. Medical Advice = seek for medical advice.</description>
        <time_frame>Within 15 days (Day 0-14) post-vaccination period following each dose</time_frame>
        <population>The analysis was performed on a subset of the Total Vaccinated Cohort. The subset of subjects was identified as 200 subjects from each country. Depending on the country, this subset was stipulated to be either the first 200 subjects enrolled irrespective of the study center or 200 subjects enrolled at selected centers.</population>
        <group_list>
          <group group_id="O1">
            <title>MMRV Group</title>
            <description>Subjects in this group received 2 doses of Priorix-Tetra vaccine, administered subcutaneously in the deltoid region of the left arm, one at Day 0 (Visit 1) and the other at Day 42 (Visit 2).</description>
          </group>
          <group group_id="O2">
            <title>OKAH Group</title>
            <description>Subjects in this group received 1 dose of Priorix at Day 0 (Visit 1) and 1 dose of Varilrix at Day 42 (Visit 2). Both vaccines were administered subcutaneously in the deltoid region of the left arm.</description>
          </group>
          <group group_id="O3">
            <title>MMR Group</title>
            <description>Subjects in this group received 2 doses of Priorix, administered subcutaneously in the deltoid region of the left arm, one at Day 0 (Visit 1) and the other at Day 42 (Visit 2).</description>
          </group>
        </group_list>
        <measure>
          <title>Phase A: Number of Subjects Reporting Fever</title>
          <description>All fever = Occurrence of any fever (measured rectally) regardless of its intensity grade or relationship to vaccination. Related fever = fever (measured rectally) assessed by the investigator to be causally related to the study vaccination. Medical Advice = seek for medical advice.</description>
          <population>The analysis was performed on a subset of the Total Vaccinated Cohort. The subset of subjects was identified as 200 subjects from each country. Depending on the country, this subset was stipulated to be either the first 200 subjects enrolled irrespective of the study center or 200 subjects enrolled at selected centers.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="784"/>
                <count group_id="O2" value="795"/>
                <count group_id="O3" value="256"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All Fever, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="784"/>
                    <count group_id="O2" value="795"/>
                    <count group_id="O3" value="256"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="450"/>
                    <measurement group_id="O2" value="354"/>
                    <measurement group_id="O3" value="102"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Fever, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="784"/>
                    <count group_id="O2" value="795"/>
                    <count group_id="O3" value="256"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="328"/>
                    <measurement group_id="O2" value="226"/>
                    <measurement group_id="O3" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Fever ≥ 38°C, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="784"/>
                    <count group_id="O2" value="795"/>
                    <count group_id="O3" value="256"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="328"/>
                    <measurement group_id="O2" value="226"/>
                    <measurement group_id="O3" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Fever &gt; 38.5°C, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="784"/>
                    <count group_id="O2" value="795"/>
                    <count group_id="O3" value="256"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="216"/>
                    <measurement group_id="O2" value="134"/>
                    <measurement group_id="O3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Fever &gt; 39°C, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="784"/>
                    <count group_id="O2" value="795"/>
                    <count group_id="O3" value="256"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="135"/>
                    <measurement group_id="O2" value="82"/>
                    <measurement group_id="O3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Fever &gt; 39.5°C, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="784"/>
                    <count group_id="O2" value="795"/>
                    <count group_id="O3" value="256"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                    <measurement group_id="O2" value="42"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Fever &gt; 40°C, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="784"/>
                    <count group_id="O2" value="795"/>
                    <count group_id="O3" value="256"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever ≥ 38°C, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="784"/>
                    <count group_id="O2" value="795"/>
                    <count group_id="O3" value="256"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="449"/>
                    <measurement group_id="O2" value="349"/>
                    <measurement group_id="O3" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever &gt; 38.5°C, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="784"/>
                    <count group_id="O2" value="795"/>
                    <count group_id="O3" value="256"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="300"/>
                    <measurement group_id="O2" value="213"/>
                    <measurement group_id="O3" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever &gt; 39°C, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="784"/>
                    <count group_id="O2" value="795"/>
                    <count group_id="O3" value="256"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="196"/>
                    <measurement group_id="O2" value="124"/>
                    <measurement group_id="O3" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever &gt; 39.5°C, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="784"/>
                    <count group_id="O2" value="795"/>
                    <count group_id="O3" value="256"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101"/>
                    <measurement group_id="O2" value="58"/>
                    <measurement group_id="O3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever &gt; 40°C, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="784"/>
                    <count group_id="O2" value="795"/>
                    <count group_id="O3" value="256"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever Medical Advice, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="784"/>
                    <count group_id="O2" value="795"/>
                    <count group_id="O3" value="256"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="140"/>
                    <measurement group_id="O2" value="100"/>
                    <measurement group_id="O3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All Fever, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="758"/>
                    <count group_id="O2" value="773"/>
                    <count group_id="O3" value="247"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="189"/>
                    <measurement group_id="O2" value="201"/>
                    <measurement group_id="O3" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Fever, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="758"/>
                    <count group_id="O2" value="773"/>
                    <count group_id="O3" value="247"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="118"/>
                    <measurement group_id="O2" value="125"/>
                    <measurement group_id="O3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Fever ≥ 38°C, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="758"/>
                    <count group_id="O2" value="773"/>
                    <count group_id="O3" value="247"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="118"/>
                    <measurement group_id="O2" value="125"/>
                    <measurement group_id="O3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Fever &gt; 38.5°C, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="758"/>
                    <count group_id="O2" value="773"/>
                    <count group_id="O3" value="247"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="73"/>
                    <measurement group_id="O3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Fever &gt; 39°C, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="758"/>
                    <count group_id="O2" value="773"/>
                    <count group_id="O3" value="247"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="41"/>
                    <measurement group_id="O3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Fever &gt; 39.5°C, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="758"/>
                    <count group_id="O2" value="773"/>
                    <count group_id="O3" value="247"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Fever &gt; 40°C, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="758"/>
                    <count group_id="O2" value="773"/>
                    <count group_id="O3" value="247"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever ≥ 38°C, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="758"/>
                    <count group_id="O2" value="773"/>
                    <count group_id="O3" value="247"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="184"/>
                    <measurement group_id="O2" value="200"/>
                    <measurement group_id="O3" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever &gt; 38.5°C, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="758"/>
                    <count group_id="O2" value="773"/>
                    <count group_id="O3" value="247"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="101"/>
                    <measurement group_id="O2" value="110"/>
                    <measurement group_id="O3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever &gt; 39°C, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="758"/>
                    <count group_id="O2" value="773"/>
                    <count group_id="O3" value="247"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62"/>
                    <measurement group_id="O2" value="65"/>
                    <measurement group_id="O3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever &gt; 39.5°C, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="758"/>
                    <count group_id="O2" value="773"/>
                    <count group_id="O3" value="247"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="35"/>
                    <measurement group_id="O3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever &gt; 40°C, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="758"/>
                    <count group_id="O2" value="773"/>
                    <count group_id="O3" value="247"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever Medical Advice, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="758"/>
                    <count group_id="O2" value="773"/>
                    <count group_id="O3" value="247"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                    <measurement group_id="O2" value="48"/>
                    <measurement group_id="O3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase A: Number of Subjects Reporting Solicited Local Symptoms</title>
        <description>Solicited local symptoms assessed were pain, redness and swelling. Any solicited local symptom = Occurrence of any local symptom regardless of their intensity grade. Grade 3 pain = Cried when limb was moved/spontaneously painful. Grade 3 redness and swelling = greater than (&gt;) 20 mm.</description>
        <time_frame>4 days post-vaccination period following each dose</time_frame>
        <population>The analysis was performed on a subset of the Total Vaccinated Cohort. The subset of subjects was identified as 200 subjects from each country. Depending on the country, this subset was stipulated to be either the first 200 subjects enrolled irrespective of the study center or 200 subjects enrolled at selected centers.</population>
        <group_list>
          <group group_id="O1">
            <title>MMRV Group</title>
            <description>Subjects in this group received 2 doses of Priorix-Tetra vaccine, administered subcutaneously in the deltoid region of the left arm, one at Day 0 (Visit 1) and the other at Day 42 (Visit 2).</description>
          </group>
          <group group_id="O2">
            <title>OKAH Group</title>
            <description>Subjects in this group received 1 dose of Priorix at Day 0 (Visit 1) and 1 dose of Varilrix at Day 42 (Visit 2). Both vaccines were administered subcutaneously in the deltoid region of the left arm.</description>
          </group>
          <group group_id="O3">
            <title>MMR Group</title>
            <description>Subjects in this group received 2 doses of Priorix, administered subcutaneously in the deltoid region of the left arm, one at Day 0 (Visit 1) and the other at Day 42 (Visit 2).</description>
          </group>
        </group_list>
        <measure>
          <title>Phase A: Number of Subjects Reporting Solicited Local Symptoms</title>
          <description>Solicited local symptoms assessed were pain, redness and swelling. Any solicited local symptom = Occurrence of any local symptom regardless of their intensity grade. Grade 3 pain = Cried when limb was moved/spontaneously painful. Grade 3 redness and swelling = greater than (&gt;) 20 mm.</description>
          <population>The analysis was performed on a subset of the Total Vaccinated Cohort. The subset of subjects was identified as 200 subjects from each country. Depending on the country, this subset was stipulated to be either the first 200 subjects enrolled irrespective of the study center or 200 subjects enrolled at selected centers.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="782"/>
                <count group_id="O2" value="796"/>
                <count group_id="O3" value="256"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Pain, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="782"/>
                    <count group_id="O2" value="796"/>
                    <count group_id="O3" value="256"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74"/>
                    <measurement group_id="O2" value="83"/>
                    <measurement group_id="O3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Pain, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="782"/>
                    <count group_id="O2" value="796"/>
                    <count group_id="O3" value="256"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Redness, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="782"/>
                    <count group_id="O2" value="796"/>
                    <count group_id="O3" value="256"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="137"/>
                    <measurement group_id="O2" value="154"/>
                    <measurement group_id="O3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Redness, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="782"/>
                    <count group_id="O2" value="796"/>
                    <count group_id="O3" value="256"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Swelling, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="782"/>
                    <count group_id="O2" value="796"/>
                    <count group_id="O3" value="256"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="37"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Swelling, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="782"/>
                    <count group_id="O2" value="796"/>
                    <count group_id="O3" value="256"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Pain, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="758"/>
                    <count group_id="O2" value="774"/>
                    <count group_id="O3" value="247"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91"/>
                    <measurement group_id="O2" value="63"/>
                    <measurement group_id="O3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Pain, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="758"/>
                    <count group_id="O2" value="774"/>
                    <count group_id="O3" value="247"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Redness, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="758"/>
                    <count group_id="O2" value="774"/>
                    <count group_id="O3" value="247"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="188"/>
                    <measurement group_id="O2" value="106"/>
                    <measurement group_id="O3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Redness, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="758"/>
                    <count group_id="O2" value="774"/>
                    <count group_id="O3" value="247"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Swelling, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="758"/>
                    <count group_id="O2" value="774"/>
                    <count group_id="O3" value="247"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72"/>
                    <measurement group_id="O2" value="31"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Swelling, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="758"/>
                    <count group_id="O2" value="774"/>
                    <count group_id="O3" value="247"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase A: Number of Subjects Reporting Meningism</title>
        <description>Any = Occurrence of meningism regardless of its intensity grade. Grade 3 meningism = Prevented normal, everyday activities. Related = Assessed by the investigator to be causally related to the study vaccination.</description>
        <time_frame>Within 43 days (Day 0-42) post-vaccination period following each dose</time_frame>
        <population>The analysis was performed on a subset of the Total Vaccinated Cohort. The subset of subjects was identified as 200 subjects from each country. Depending on the country, this subset was stipulated to be either the first 200 subjects enrolled irrespective of the study center or 200 subjects enrolled at selected centers.</population>
        <group_list>
          <group group_id="O1">
            <title>MMRV Group</title>
            <description>Subjects in this group received 2 doses of Priorix-Tetra vaccine, administered subcutaneously in the deltoid region of the left arm, one at Day 0 (Visit 1) and the other at Day 42 (Visit 2).</description>
          </group>
          <group group_id="O2">
            <title>OKAH Group</title>
            <description>Subjects in this group received 1 dose of Priorix at Day 0 (Visit 1) and 1 dose of Varilrix at Day 42 (Visit 2). Both vaccines were administered subcutaneously in the deltoid region of the left arm.</description>
          </group>
          <group group_id="O3">
            <title>MMR Group</title>
            <description>Subjects in this group received 2 doses of Priorix, administered subcutaneously in the deltoid region of the left arm, one at Day 0 (Visit 1) and the other at Day 42 (Visit 2).</description>
          </group>
        </group_list>
        <measure>
          <title>Phase A: Number of Subjects Reporting Meningism</title>
          <description>Any = Occurrence of meningism regardless of its intensity grade. Grade 3 meningism = Prevented normal, everyday activities. Related = Assessed by the investigator to be causally related to the study vaccination.</description>
          <population>The analysis was performed on a subset of the Total Vaccinated Cohort. The subset of subjects was identified as 200 subjects from each country. Depending on the country, this subset was stipulated to be either the first 200 subjects enrolled irrespective of the study center or 200 subjects enrolled at selected centers.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="784"/>
                <count group_id="O2" value="795"/>
                <count group_id="O3" value="256"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Meningism, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="784"/>
                    <count group_id="O2" value="795"/>
                    <count group_id="O3" value="256"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Meningism, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="784"/>
                    <count group_id="O2" value="795"/>
                    <count group_id="O3" value="256"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Meningism, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="784"/>
                    <count group_id="O2" value="795"/>
                    <count group_id="O3" value="256"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Meningism, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="758"/>
                    <count group_id="O2" value="773"/>
                    <count group_id="O3" value="247"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Meningism, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="758"/>
                    <count group_id="O2" value="773"/>
                    <count group_id="O3" value="247"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Meningism, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="758"/>
                    <count group_id="O2" value="773"/>
                    <count group_id="O3" value="247"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase A: Number of Subjects Reporting Parotitis</title>
        <description>Any = Occurrence of parotitis regardless of its intensity grade. Grade 3 parotitis = Swelling with accompanying general symptoms. Related = Assessed by the investigator to be causally related to the study.</description>
        <time_frame>Within 43 days (Day 0-42) post-vaccination period following each dose</time_frame>
        <population>The analysis was performed on a subset of the Total Vaccinated Cohort. The subset of subjects was identified as 200 subjects from each country. Depending on the country, this subset was stipulated to be either the first 200 subjects enrolled irrespective of the study center or 200 subjects enrolled at selected centers.</population>
        <group_list>
          <group group_id="O1">
            <title>MMRV Group</title>
            <description>Subjects in this group received 2 doses of Priorix-Tetra vaccine, administered subcutaneously in the deltoid region of the left arm, one at Day 0 (Visit 1) and the other at Day 42 (Visit 2).</description>
          </group>
          <group group_id="O2">
            <title>OKAH Group</title>
            <description>Subjects in this group received 1 dose of Priorix at Day 0 (Visit 1) and 1 dose of Varilrix at Day 42 (Visit 2). Both vaccines were administered subcutaneously in the deltoid region of the left arm.</description>
          </group>
          <group group_id="O3">
            <title>MMR Group</title>
            <description>Subjects in this group received 2 doses of Priorix, administered subcutaneously in the deltoid region of the left arm, one at Day 0 (Visit 1) and the other at Day 42 (Visit 2).</description>
          </group>
        </group_list>
        <measure>
          <title>Phase A: Number of Subjects Reporting Parotitis</title>
          <description>Any = Occurrence of parotitis regardless of its intensity grade. Grade 3 parotitis = Swelling with accompanying general symptoms. Related = Assessed by the investigator to be causally related to the study.</description>
          <population>The analysis was performed on a subset of the Total Vaccinated Cohort. The subset of subjects was identified as 200 subjects from each country. Depending on the country, this subset was stipulated to be either the first 200 subjects enrolled irrespective of the study center or 200 subjects enrolled at selected centers.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="784"/>
                <count group_id="O2" value="795"/>
                <count group_id="O3" value="256"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Parotitis, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="784"/>
                    <count group_id="O2" value="795"/>
                    <count group_id="O3" value="256"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Parotitis, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="784"/>
                    <count group_id="O2" value="795"/>
                    <count group_id="O3" value="256"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Parotitis, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="784"/>
                    <count group_id="O2" value="795"/>
                    <count group_id="O3" value="256"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Parotitis, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="758"/>
                    <count group_id="O2" value="773"/>
                    <count group_id="O3" value="247"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 Parotitis, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="758"/>
                    <count group_id="O2" value="773"/>
                    <count group_id="O3" value="247"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related Parotitis, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="758"/>
                    <count group_id="O2" value="773"/>
                    <count group_id="O3" value="247"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase A: Number of Subjects Reporting Rash</title>
        <description>Any = Occurrence of rash regardless of its intensity grade. Grade 3 rash = 101-500 lesions. Grade 4 rash = &gt; 500 lesions. Related rash = Assessed by the investigator to be causally related to the study vaccination.</description>
        <time_frame>Within 43 days (Day 0-42) post-vaccination period following each dose</time_frame>
        <population>The analysis was performed on a subset of the Total Vaccinated Cohort. The subset of subjects was identified as 200 subjects from each country. Depending on the country, this subset was stipulated to be either the first 200 subjects enrolled irrespective of the study center or 200 subjects enrolled at selected centers.</population>
        <group_list>
          <group group_id="O1">
            <title>MMRV Group</title>
            <description>Subjects in this group received 2 doses of Priorix-Tetra vaccine, administered subcutaneously in the deltoid region of the left arm, one at Day 0 (Visit 1) and the other at Day 42 (Visit 2).</description>
          </group>
          <group group_id="O2">
            <title>OKAH Group</title>
            <description>Subjects in this group received 1 dose of Priorix at Day 0 (Visit 1) and 1 dose of Varilrix at Day 42 (Visit 2). Both vaccines were administered subcutaneously in the deltoid region of the left arm.</description>
          </group>
          <group group_id="O3">
            <title>MMR Group</title>
            <description>Subjects in this group received 2 doses of Priorix, administered subcutaneously in the deltoid region of the left arm, one at Day 0 (Visit 1) and the other at Day 42 (Visit 2).</description>
          </group>
        </group_list>
        <measure>
          <title>Phase A: Number of Subjects Reporting Rash</title>
          <description>Any = Occurrence of rash regardless of its intensity grade. Grade 3 rash = 101-500 lesions. Grade 4 rash = &gt; 500 lesions. Related rash = Assessed by the investigator to be causally related to the study vaccination.</description>
          <population>The analysis was performed on a subset of the Total Vaccinated Cohort. The subset of subjects was identified as 200 subjects from each country. Depending on the country, this subset was stipulated to be either the first 200 subjects enrolled irrespective of the study center or 200 subjects enrolled at selected centers.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="784"/>
                <count group_id="O2" value="795"/>
                <count group_id="O3" value="256"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Localized or Generalized,Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="784"/>
                    <count group_id="O2" value="795"/>
                    <count group_id="O3" value="256"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82"/>
                    <measurement group_id="O2" value="84"/>
                    <measurement group_id="O3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Localized, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="784"/>
                    <count group_id="O2" value="795"/>
                    <count group_id="O3" value="256"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Localized Admin. site, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="784"/>
                    <count group_id="O2" value="795"/>
                    <count group_id="O3" value="256"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Localized Other site, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="784"/>
                    <count group_id="O2" value="795"/>
                    <count group_id="O3" value="256"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Generalized, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="784"/>
                    <count group_id="O2" value="795"/>
                    <count group_id="O3" value="256"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68"/>
                    <measurement group_id="O2" value="69"/>
                    <measurement group_id="O3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Generalized With fever, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="784"/>
                    <count group_id="O2" value="795"/>
                    <count group_id="O3" value="256"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="41"/>
                    <measurement group_id="O3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Generalized Measles/Rubella, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="784"/>
                    <count group_id="O2" value="795"/>
                    <count group_id="O3" value="256"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Generalized Grade 3/4, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="784"/>
                    <count group_id="O2" value="795"/>
                    <count group_id="O3" value="256"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Generalized Grade 4, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="784"/>
                    <count group_id="O2" value="795"/>
                    <count group_id="O3" value="256"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Generalized Related, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="784"/>
                    <count group_id="O2" value="795"/>
                    <count group_id="O3" value="256"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="32"/>
                    <measurement group_id="O3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Localized or Generalized,Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="758"/>
                    <count group_id="O2" value="773"/>
                    <count group_id="O3" value="247"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="36"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Localized, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="758"/>
                    <count group_id="O2" value="773"/>
                    <count group_id="O3" value="247"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Localized Admin. site, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="758"/>
                    <count group_id="O2" value="773"/>
                    <count group_id="O3" value="247"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Localized Other site, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="758"/>
                    <count group_id="O2" value="773"/>
                    <count group_id="O3" value="247"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Generalized, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="758"/>
                    <count group_id="O2" value="773"/>
                    <count group_id="O3" value="247"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Generalized With fever, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="758"/>
                    <count group_id="O2" value="773"/>
                    <count group_id="O3" value="247"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Generalized Measles/Rubella, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="758"/>
                    <count group_id="O2" value="773"/>
                    <count group_id="O3" value="247"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Generalized Grade 3/4, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="758"/>
                    <count group_id="O2" value="773"/>
                    <count group_id="O3" value="247"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Generalized Grade 4, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="758"/>
                    <count group_id="O2" value="773"/>
                    <count group_id="O3" value="247"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Generalized Related, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="758"/>
                    <count group_id="O2" value="773"/>
                    <count group_id="O3" value="247"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase A: Number of Subjects With Suspected Sign of Meningism Including Febrile Convulsions</title>
        <description>Any = Occurrence of meningism including febrile convulsions regardless of intensity grade.</description>
        <time_frame>Within 43 days (Day 0-42) post-vaccination period following each dose</time_frame>
        <population>The analysis was performed on a subset of the Total Vaccinated Cohort. The subset of subjects was identified as 200 subjects from each country. Depending on the country, this subset was stipulated to be either the first 200 subjects enrolled irrespective of the study center or 200 subjects enrolled at selected centers.</population>
        <group_list>
          <group group_id="O1">
            <title>MMRV Group</title>
            <description>Subjects in this group received 2 doses of Priorix-Tetra vaccine, administered subcutaneously in the deltoid region of the left arm, one at Day 0 (Visit 1) and the other at Day 42 (Visit 2).</description>
          </group>
          <group group_id="O2">
            <title>OKAH Group</title>
            <description>Subjects in this group received 1 dose of Priorix at Day 0 (Visit 1) and 1 dose of Varilrix at Day 42 (Visit 2). Both vaccines were administered subcutaneously in the deltoid region of the left arm.</description>
          </group>
          <group group_id="O3">
            <title>MMR Group</title>
            <description>Subjects in this group received 2 doses of Priorix, administered subcutaneously in the deltoid region of the left arm, one at Day 0 (Visit 1) and the other at Day 42 (Visit 2).</description>
          </group>
        </group_list>
        <measure>
          <title>Phase A: Number of Subjects With Suspected Sign of Meningism Including Febrile Convulsions</title>
          <description>Any = Occurrence of meningism including febrile convulsions regardless of intensity grade.</description>
          <population>The analysis was performed on a subset of the Total Vaccinated Cohort. The subset of subjects was identified as 200 subjects from each country. Depending on the country, this subset was stipulated to be either the first 200 subjects enrolled irrespective of the study center or 200 subjects enrolled at selected centers.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="784"/>
                <count group_id="O2" value="795"/>
                <count group_id="O3" value="256"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Meningism including febrile convulsions, Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="784"/>
                    <count group_id="O2" value="795"/>
                    <count group_id="O3" value="256"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Meningism including febrile convulsions, Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="758"/>
                    <count group_id="O2" value="773"/>
                    <count group_id="O3" value="247"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase A: Number of Subjects Reporting Unsolicited Adverse Events (AEs)</title>
        <description>Unsolicited AE assessed included any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any = Occurrence of any unsolicited symptom regardless of intensity grade or relation to vaccination.</description>
        <time_frame>Within 43 days (Day 0-42) post-vaccination period following each dose</time_frame>
        <population>The analysis was performed on a subset of the Total Vaccinated Cohort. The subset of subjects was identified as 200 subjects from each country. Depending on the country, this subset was stipulated to be either the first 200 subjects enrolled irrespective of the study center or 200 subjects enrolled at selected centers.</population>
        <group_list>
          <group group_id="O1">
            <title>MMRV Group</title>
            <description>Subjects in this group received 2 doses of Priorix-Tetra vaccine, administered subcutaneously in the deltoid region of the left arm, one at Day 0 (Visit 1) and the other at Day 42 (Visit 2).</description>
          </group>
          <group group_id="O2">
            <title>OKAH Group</title>
            <description>Subjects in this group received 1 dose of Priorix at Day 0 (Visit 1) and 1 dose of Varilrix at Day 42 (Visit 2). Both vaccines were administered subcutaneously in the deltoid region of the left arm.</description>
          </group>
          <group group_id="O3">
            <title>MMR Group</title>
            <description>Subjects in this group received 2 doses of Priorix, administered subcutaneously in the deltoid region of the left arm, one at Day 0 (Visit 1) and the other at Day 42 (Visit 2).</description>
          </group>
        </group_list>
        <measure>
          <title>Phase A: Number of Subjects Reporting Unsolicited Adverse Events (AEs)</title>
          <description>Unsolicited AE assessed included any AE reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any = Occurrence of any unsolicited symptom regardless of intensity grade or relation to vaccination.</description>
          <population>The analysis was performed on a subset of the Total Vaccinated Cohort. The subset of subjects was identified as 200 subjects from each country. Depending on the country, this subset was stipulated to be either the first 200 subjects enrolled irrespective of the study center or 200 subjects enrolled at selected centers.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="807"/>
                <count group_id="O2" value="812"/>
                <count group_id="O3" value="268"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AE(s), Dose 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="807"/>
                    <count group_id="O2" value="812"/>
                    <count group_id="O3" value="268"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="301"/>
                    <measurement group_id="O2" value="303"/>
                    <measurement group_id="O3" value="82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any AE(s), Dose 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="777"/>
                    <count group_id="O2" value="788"/>
                    <count group_id="O3" value="253"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="239"/>
                    <measurement group_id="O2" value="258"/>
                    <measurement group_id="O3" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase A: Number of Subjects Reporting Serious Adverse Events (SAEs)</title>
        <description>SAEs assessed included medical occurrences that resulted in death, were life-threatening, required hospitalisation or prolongation of hospitalisation or resulted in disability/incapacity. Any SAE = occurrence of SAE regardless of intensity grade or relation to vaccination.</description>
        <time_frame>From Day 0 until the end of Phase A (Year 2)</time_frame>
        <population>The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>MMRV Group</title>
            <description>Subjects in this group received 2 doses of Priorix-Tetra vaccine, administered subcutaneously in the deltoid region of the left arm, one at Day 0 (Visit 1) and the other at Day 42 (Visit 2).</description>
          </group>
          <group group_id="O2">
            <title>OKAH Group</title>
            <description>Subjects in this group received 1 dose of Priorix at Day 0 (Visit 1) and 1 dose of Varilrix at Day 42 (Visit 2). Both vaccines were administered subcutaneously in the deltoid region of the left arm.</description>
          </group>
          <group group_id="O3">
            <title>MMR Group</title>
            <description>Subjects in this group received 2 doses of Priorix, administered subcutaneously in the deltoid region of the left arm, one at Day 0 (Visit 1) and the other at Day 42 (Visit 2).</description>
          </group>
        </group_list>
        <measure>
          <title>Phase A: Number of Subjects Reporting Serious Adverse Events (SAEs)</title>
          <description>SAEs assessed included medical occurrences that resulted in death, were life-threatening, required hospitalisation or prolongation of hospitalisation or resulted in disability/incapacity. Any SAE = occurrence of SAE regardless of intensity grade or relation to vaccination.</description>
          <population>The analysis was performed on the Total Vaccinated cohort, which included all vaccinated subjects.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2489"/>
                <count group_id="O2" value="2487"/>
                <count group_id="O3" value="827"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="473"/>
                    <measurement group_id="O2" value="480"/>
                    <measurement group_id="O3" value="148"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase A: Health Economics Analysis of Factors Leading to Indirect Costs Due to Varicella Illness</title>
        <description>Parameters assessed: 1. Number of hours lost from work by parents/guardians as a result of taking care of their child due to varicella. 2. Number of hours the child lost attendance in: day care/childminder, school, or in any extra-curricular activities (e.g. sports or recreation or any type of organised leisure activities) due to varicella. 3. Number of hours spent by a nurse, a babysitter or any type of existing paid caregiver to look after the child (if applicable).</description>
        <time_frame>During Phase A (from Day 0 up to Year 2)</time_frame>
        <population>The analysis was performed on the ATP Cohort for Efficacy (Phase A), which included all evaluable subjects who had efficacy follow-up starting from 42 days post dose 2.</population>
        <group_list>
          <group group_id="O1">
            <title>MMRV Group</title>
            <description>Subjects in this group received 2 doses of Priorix-Tetra vaccine, administered subcutaneously in the deltoid region of the left arm, one at Day 0 (Visit 1) and the other at Day 42 (Visit 2).</description>
          </group>
          <group group_id="O2">
            <title>OKAH Group</title>
            <description>Subjects in this group received 1 dose of Priorix at Day 0 (Visit 1) and 1 dose of Varilrix at Day 42 (Visit 2). Both vaccines were administered subcutaneously in the deltoid region of the left arm.</description>
          </group>
          <group group_id="O3">
            <title>MMR Group</title>
            <description>Subjects in this group received 2 doses of Priorix, administered subcutaneously in the deltoid region of the left arm, one at Day 0 (Visit 1) and the other at Day 42 (Visit 2).</description>
          </group>
        </group_list>
        <measure>
          <title>Phase A: Health Economics Analysis of Factors Leading to Indirect Costs Due to Varicella Illness</title>
          <description>Parameters assessed: 1. Number of hours lost from work by parents/guardians as a result of taking care of their child due to varicella. 2. Number of hours the child lost attendance in: day care/childminder, school, or in any extra-curricular activities (e.g. sports or recreation or any type of organised leisure activities) due to varicella. 3. Number of hours spent by a nurse, a babysitter or any type of existing paid caregiver to look after the child (if applicable).</description>
          <population>The analysis was performed on the ATP Cohort for Efficacy (Phase A), which included all evaluable subjects who had efficacy follow-up starting from 42 days post dose 2.</population>
          <units>Hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="246"/>
                <count group_id="O3" value="201"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Time lost from work [hours]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.5" spread="22.9"/>
                    <measurement group_id="O2" value="40.5" spread="31.4"/>
                    <measurement group_id="O3" value="48.1" spread="35.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time lost for subjects [hours]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.4" spread="86.0"/>
                    <measurement group_id="O2" value="49.5" spread="31.9"/>
                    <measurement group_id="O3" value="54.5" spread="36.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time of requested assistance [hours]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.0" spread="31.1"/>
                    <measurement group_id="O2" value="35.2" spread="51.6"/>
                    <measurement group_id="O3" value="35.4" spread="31.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase B: Number of Subjects With Confirmed Varicella Case</title>
        <description>Confirmed varicella case = A case that met the clinical case definition at least in the opinion of the investigator and was confirmed by laboratory test [PCR (+)] OR a case that met the clinical definition confirmed by the IDMC and was epidemiologically linked [Epi (+)] to a valid index case.</description>
        <time_frame>From the beginning of Phase B (Year 2) up to study end (Year 10)</time_frame>
        <population>The analysis was performed on the ATP Cohort for Efficacy (Phase B), which included all evaluable subjects who had efficacy follow-up from the period when Phase A was completed.</population>
        <group_list>
          <group group_id="O1">
            <title>MMRV Group</title>
            <description>Subjects in this group received 2 doses of Priorix-Tetra vaccine, administered subcutaneously in the deltoid region of the left arm, one at Day 0 (Visit 1) and the other at Day 42 (Visit 2).</description>
          </group>
          <group group_id="O2">
            <title>OKAH Group</title>
            <description>Subjects in this group received 1 dose of Priorix at Day 0 (Visit 1) and 1 dose of Varilrix at Day 42 (Visit 2). Both vaccines were administered subcutaneously in the deltoid region of the left arm.</description>
          </group>
          <group group_id="O3">
            <title>MMR Group</title>
            <description>Subjects in this group received 2 doses of Priorix, administered subcutaneously in the deltoid region of the left arm, one at Day 0 (Visit 1) and the other at Day 42 (Visit 2).</description>
          </group>
        </group_list>
        <measure>
          <title>Phase B: Number of Subjects With Confirmed Varicella Case</title>
          <description>Confirmed varicella case = A case that met the clinical case definition at least in the opinion of the investigator and was confirmed by laboratory test [PCR (+)] OR a case that met the clinical definition confirmed by the IDMC and was epidemiologically linked [Epi (+)] to a valid index case.</description>
          <population>The analysis was performed on the ATP Cohort for Efficacy (Phase B), which included all evaluable subjects who had efficacy follow-up from the period when Phase A was completed.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1800"/>
                <count group_id="O2" value="1591"/>
                <count group_id="O3" value="396"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="225"/>
                    <measurement group_id="O3" value="149"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>VE was measured by calculating the relative risk of a confirmed varicella case in a vaccine group compared to a confirmed varicella case in the control group.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>To demonstrate at least 60% VE, with respect to confirmed varicella disease over at least a two-year period of follow-up (beginning 42 days post dose 2) of Priorix-Tetra as compared to Priorix).</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>Regression, Cox</method>
            <param_type>Vaccine Efficacy</param_type>
            <param_value>95.855</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>94.075</ci_lower_limit>
            <ci_upper_limit>97.101</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>VE was measured by calculating the relative risk of a confirmed varicella case in a vaccine group compared to a confirmed varicella case in the control group.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>To demonstrate at least 60% VE, with respect to confirmed varicella disease over at least a two-year period of follow-up (beginning 42 days post dose 2) of Varilrix as compared to Priorix).</non_inferiority_desc>
            <p_value>0.1265</p_value>
            <method>Regression, Cox</method>
            <param_type>Vaccine Efficacy</param_type>
            <param_value>69.812</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>62.848</ci_lower_limit>
            <ci_upper_limit>75.470</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase B: Number of Subjects With Moderate or Severe Confirmed Varicella Case</title>
        <description>Confirmed varicella case = A case that met the clinical case definition at least in the opinion of the investigator and was confirmed by laboratory test [PCR (+)] OR a case that met the clinical definition confirmed by the IDMC and was epidemiologically linked [Epi (+)] to a valid index case. Moderately severe disease = 8-15 points; severe disease: ≥ 16 points (scored by IDMC using the modified Vázquez scale).</description>
        <time_frame>From the beginning of Phase B (Year 2) up to study end (Year 10)</time_frame>
        <population>The analysis was performed on the ATP Cohort for Efficacy (Phase B), which included all evaluable subjects who had efficacy follow-up from the period when Phase A was completed.</population>
        <group_list>
          <group group_id="O1">
            <title>MMRV Group</title>
            <description>Subjects in this group received 2 doses of Priorix-Tetra vaccine, administered subcutaneously in the deltoid region of the left arm, one at Day 0 (Visit 1) and the other at Day 42 (Visit 2).</description>
          </group>
          <group group_id="O2">
            <title>OKAH Group</title>
            <description>Subjects in this group received 1 dose of Priorix at Day 0 (Visit 1) and 1 dose of Varilrix at Day 42 (Visit 2). Both vaccines were administered subcutaneously in the deltoid region of the left arm.</description>
          </group>
          <group group_id="O3">
            <title>MMR Group</title>
            <description>Subjects in this group received 2 doses of Priorix, administered subcutaneously in the deltoid region of the left arm, one at Day 0 (Visit 1) and the other at Day 42 (Visit 2).</description>
          </group>
        </group_list>
        <measure>
          <title>Phase B: Number of Subjects With Moderate or Severe Confirmed Varicella Case</title>
          <description>Confirmed varicella case = A case that met the clinical case definition at least in the opinion of the investigator and was confirmed by laboratory test [PCR (+)] OR a case that met the clinical definition confirmed by the IDMC and was epidemiologically linked [Epi (+)] to a valid index case. Moderately severe disease = 8-15 points; severe disease: ≥ 16 points (scored by IDMC using the modified Vázquez scale).</description>
          <population>The analysis was performed on the ATP Cohort for Efficacy (Phase B), which included all evaluable subjects who had efficacy follow-up from the period when Phase A was completed.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2279"/>
                <count group_id="O2" value="2266"/>
                <count group_id="O3" value="744"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="67"/>
                    <measurement group_id="O3" value="176"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>VE was measured by calculating the relative risk of a moderate or severe confirmed varicella case in a vaccine group compared to a moderate or severe confirmed varicella case in the control group.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>To demonstrate at least 60% VE, with respect to confirmed varicella disease over at least a two-year period of follow-up (beginning 42 days post dose 2) of Priorix-Tetra as compared to Priorix).</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>Regression, Cox</method>
            <param_type>Vaccine Efficacy</param_type>
            <param_value>99.072</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>97.907</ci_lower_limit>
            <ci_upper_limit>99.589</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>VE was measured by calculating the relative risk of a moderate or severe confirmed varicella case in a vaccine group compared to a moderate or severe confirmed varicella case in the control group.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>To demonstrate at least 60% VE, with respect to confirmed varicella disease over at least a two-year period of follow-up (beginning 42 days post dose 2) of Varilrix as compared to Priorix).</non_inferiority_desc>
            <p_value>0.1265</p_value>
            <method>Regression, Cox</method>
            <param_type>Vaccine Efficacy</param_type>
            <param_value>89.532</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>86.126</ci_lower_limit>
            <ci_upper_limit>92.102</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase B: Number of Subjects With Probable or Confirmed Varicella Case</title>
        <description>Probable or confirmed varicella = A case that met the clinical case definition (as determined by the IDMC) but was not laboratory confirmed [PCR (‑)] AND was not epidemiologically linked [Epi (‑)] to another probable or confirmed case.</description>
        <time_frame>From the beginning of Phase B (Year 2) up to study end (Year 10)</time_frame>
        <population>The analysis was performed on the ATP Cohort for Efficacy (Phase B), which included all evaluable subjects who had efficacy follow-up from the period when Phase A was completed.</population>
        <group_list>
          <group group_id="O1">
            <title>MMRV Group</title>
            <description>Subjects in this group received 2 doses of Priorix-Tetra vaccine, administered subcutaneously in the deltoid region of the left arm, one at Day 0 (Visit 1) and the other at Day 42 (Visit 2).</description>
          </group>
          <group group_id="O2">
            <title>OKAH Group</title>
            <description>Subjects in this group received 1 dose of Priorix at Day 0 (Visit 1) and 1 dose of Varilrix at Day 42 (Visit 2). Both vaccines were administered subcutaneously in the deltoid region of the left arm.</description>
          </group>
          <group group_id="O3">
            <title>MMR Group</title>
            <description>Subjects in this group received 2 doses of Priorix, administered subcutaneously in the deltoid region of the left arm, one at Day 0 (Visit 1) and the other at Day 42 (Visit 2).</description>
          </group>
        </group_list>
        <measure>
          <title>Phase B: Number of Subjects With Probable or Confirmed Varicella Case</title>
          <description>Probable or confirmed varicella = A case that met the clinical case definition (as determined by the IDMC) but was not laboratory confirmed [PCR (‑)] AND was not epidemiologically linked [Epi (‑)] to another probable or confirmed case.</description>
          <population>The analysis was performed on the ATP Cohort for Efficacy (Phase B), which included all evaluable subjects who had efficacy follow-up from the period when Phase A was completed.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1800"/>
                <count group_id="O2" value="1591"/>
                <count group_id="O3" value="396"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="237"/>
                    <measurement group_id="O3" value="152"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>VE was measured by calculating the relative risk of a probable or confirmed varicella case in a vaccine group compared to a probable or confirmed varicella case in the control group.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>To demonstrate at least 60% VE, with respect to confirmed varicella disease over at least a two-year period of follow-up (beginning 42 days post dose 2) of Priorix-Tetra as compared to Priorix).</non_inferiority_desc>
            <p_value>&lt;0.0001</p_value>
            <method>Regression, Cox</method>
            <param_type>Vaccine Efficacy</param_type>
            <param_value>94.816</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>92.838</ci_lower_limit>
            <ci_upper_limit>96.248</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>VE was measured by calculating the relative risk of a probable or confirmed varicella case in a vaccine group compared to a probable or confirmed varicella case in the control group.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>To demonstrate at least 60% VE, with respect to confirmed varicella disease over at least a two-year period of follow-up (beginning 42 days post dose 2) of Varilrix as compared to Priorix).</non_inferiority_desc>
            <p_value>0.1265</p_value>
            <method>Regression, Cox</method>
            <param_type>Vaccine Efficacy</param_type>
            <param_value>68.932</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>61.893</ci_lower_limit>
            <ci_upper_limit>74.671</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase B: Characteristics of Varicella Cases</title>
        <description>Varicella cases were characterized by type, number and character of lesions, duration of rash, incidence of fever, systemic signs, the assessment by investigator, complications, treatment, outcome and intensity of severity.</description>
        <time_frame>From the beginning of Phase B (Year 2) up to study end (Year 10)</time_frame>
        <population>The analysis was performed on the ATP Cohort for Efficacy (Phase B), which included all evaluable subjects who had efficacy follow-up from the period when Phase A was completed.</population>
        <group_list>
          <group group_id="O1">
            <title>MMRV Group</title>
            <description>Subjects in this group received 2 doses of Priorix-Tetra vaccine, administered subcutaneously in the deltoid region of the left arm, one at Day 0 (Visit 1) and the other at Day 42 (Visit 2).</description>
          </group>
          <group group_id="O2">
            <title>OKAH Group</title>
            <description>Subjects in this group received 1 dose of Priorix at Day 0 (Visit 1) and 1 dose of Varilrix at Day 42 (Visit 2). Both vaccines were administered subcutaneously in the deltoid region of the left arm.</description>
          </group>
          <group group_id="O3">
            <title>MMR Group</title>
            <description>Subjects in this group received 2 doses of Priorix, administered subcutaneously in the deltoid region of the left arm, one at Day 0 (Visit 1) and the other at Day 42 (Visit 2).</description>
          </group>
        </group_list>
        <measure>
          <title>Phase B: Characteristics of Varicella Cases</title>
          <description>Varicella cases were characterized by type, number and character of lesions, duration of rash, incidence of fever, systemic signs, the assessment by investigator, complications, treatment, outcome and intensity of severity.</description>
          <population>The analysis was performed on the ATP Cohort for Efficacy (Phase B), which included all evaluable subjects who had efficacy follow-up from the period when Phase A was completed.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="225"/>
                <count group_id="O3" value="149"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of varicella cases by subject, 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="223"/>
                    <measurement group_id="O3" value="148"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Number of varicella cases by subject, 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Varicella type, Any</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="225"/>
                    <measurement group_id="O3" value="149"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Varicella type, Confirmed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="225"/>
                    <measurement group_id="O3" value="149"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Varicella type, Confirmed PCR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="207"/>
                    <measurement group_id="O3" value="140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Varicella type, Confirmed EPI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Varicella type, Confirmed or Probable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="225"/>
                    <measurement group_id="O3" value="149"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Varicella type, No case</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash: number of lesions, 1-50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="173"/>
                    <measurement group_id="O3" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash: number of lesions, 51-100</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="35"/>
                    <measurement group_id="O3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash: number of lesions, 101-500</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash: number of lesions, 501+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash: number of lesions, Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Character of most lesions, Macular</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Character of most lesions, Papular</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="108"/>
                    <measurement group_id="O3" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Character of most lesions, Vesicular</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="100"/>
                    <measurement group_id="O3" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Character of most lesions, Haemorragic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Character of most lesions, Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration of rash, 0 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration of rash, 1-5 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="140"/>
                    <measurement group_id="O3" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration of rash, 6-10 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="67"/>
                    <measurement group_id="O3" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration of rash, 11-15 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration of rash, 16+ days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration of rash, Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Max. number of lesions [investigator], 1-50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="173"/>
                    <measurement group_id="O3" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Max. number of lesions [investigator], 51-100</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="35"/>
                    <measurement group_id="O3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Max. number of lesions [investigator], 101-500</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Max. number of lesions [investigator], 501+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Max. number of lesions [investigator], Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever, No fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="212"/>
                    <measurement group_id="O3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever, 38.8°C to 39.9°C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever, 40+ °C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systemic sign, Pain in back or abdomen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systemic sign, Interstitial pneumonia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systemic sign, Encephalitis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Assessment by investigator, Does not appear ill</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="159"/>
                    <measurement group_id="O3" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Assessment by investigator, Moderately ill</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="64"/>
                    <measurement group_id="O3" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Assessment by investigator, Severely ill</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Assessment by investigator, Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complications, Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complications, No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="222"/>
                    <measurement group_id="O3" value="147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complications, Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment, Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="115"/>
                    <measurement group_id="O3" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment, No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="106"/>
                    <measurement group_id="O3" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment, Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Outcome, Recovered/resolved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="224"/>
                    <measurement group_id="O3" value="148"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Outcome, Recovered/resolved with sequelae</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Outcome, Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intensity of severity, Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="198"/>
                    <measurement group_id="O3" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intensity of severity, Moderately severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="27"/>
                    <measurement group_id="O3" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intensity of severity, Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase B: Immune Response to Varicella Vaccine With Respect to Anti-Varicella Zoster Virus (Anti-VZV) Antibody Concentrations</title>
        <description>Anti-VZV antibody concentrations are presented as Geometric Mean Concentrations (GMCs), expressed in milliinternational units per milliliter (mIU/mL).</description>
        <time_frame>At Year 4, Year 6, Year 8 and Year 10 time points</time_frame>
        <population>The analysis was performed on the Adapted persistence cohort (Adapted ATP cohort for each specific time point).</population>
        <group_list>
          <group group_id="O1">
            <title>MMRV Group</title>
            <description>Subjects in this group received 2 doses of Priorix-Tetra vaccine, administered subcutaneously in the deltoid region of the left arm, one at Day 0 (Visit 1) and the other at Day 42 (Visit 2).</description>
          </group>
          <group group_id="O2">
            <title>OKAH Group</title>
            <description>Subjects in this group received 1 dose of Priorix at Day 0 (Visit 1) and 1 dose of Varilrix at Day 42 (Visit 2). Both vaccines were administered subcutaneously in the deltoid region of the left arm.</description>
          </group>
          <group group_id="O3">
            <title>MMR Group</title>
            <description>Subjects in this group received 2 doses of Priorix, administered subcutaneously in the deltoid region of the left arm, one at Day 0 (Visit 1) and the other at Day 42 (Visit 2).</description>
          </group>
        </group_list>
        <measure>
          <title>Phase B: Immune Response to Varicella Vaccine With Respect to Anti-Varicella Zoster Virus (Anti-VZV) Antibody Concentrations</title>
          <description>Anti-VZV antibody concentrations are presented as Geometric Mean Concentrations (GMCs), expressed in milliinternational units per milliliter (mIU/mL).</description>
          <population>The analysis was performed on the Adapted persistence cohort (Adapted ATP cohort for each specific time point).</population>
          <units>mIU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1342"/>
                <count group_id="O2" value="1142"/>
                <count group_id="O3" value="242"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-VZV, Year 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1342"/>
                    <count group_id="O2" value="1142"/>
                    <count group_id="O3" value="242"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="501.3" lower_limit="467.8" upper_limit="537.1"/>
                    <measurement group_id="O2" value="272.7" lower_limit="246.2" upper_limit="302.1"/>
                    <measurement group_id="O3" value="32.4" lower_limit="26.1" upper_limit="40.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-VZV, Year 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1292"/>
                    <count group_id="O2" value="1021"/>
                    <count group_id="O3" value="176"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="680.6" lower_limit="635.7" upper_limit="728.8"/>
                    <measurement group_id="O2" value="417.6" lower_limit="379.9" upper_limit="459.0"/>
                    <measurement group_id="O3" value="91.8" lower_limit="66.3" upper_limit="126.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-VZV, Year 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1146"/>
                    <count group_id="O2" value="828"/>
                    <count group_id="O3" value="117"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="512.5" lower_limit="480.3" upper_limit="546.8"/>
                    <measurement group_id="O2" value="418.5" lower_limit="383.2" upper_limit="457.1"/>
                    <measurement group_id="O3" value="146.9" lower_limit="99.6" upper_limit="216.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-VZV, Year 10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1169"/>
                    <count group_id="O2" value="831"/>
                    <count group_id="O3" value="111"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="471.3" lower_limit="443.2" upper_limit="501.2"/>
                    <measurement group_id="O2" value="404.6" lower_limit="373.0" upper_limit="438.8"/>
                    <measurement group_id="O3" value="219.6" lower_limit="149.2" upper_limit="323.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase B: Number of Subjects With Anti-VZV Antibody Concentrations Above the Cut-off Value</title>
        <description>The anti-VZV antibody concentration cut-off value assessed was greater than or equal to (≥) 25 mIU/mL, in the sera of subjects seronegative before vaccination.</description>
        <time_frame>At Year 4, Year 6, Year 8 and Year 10 time points</time_frame>
        <population>The analysis was performed on the Adapted persistence cohort (Adapted ATP cohort for each specific time point).</population>
        <group_list>
          <group group_id="O1">
            <title>MMRV Group</title>
            <description>Subjects in this group received 2 doses of Priorix-Tetra vaccine, administered subcutaneously in the deltoid region of the left arm, one at Day 0 (Visit 1) and the other at Day 42 (Visit 2).</description>
          </group>
          <group group_id="O2">
            <title>OKAH Group</title>
            <description>Subjects in this group received 1 dose of Priorix at Day 0 (Visit 1) and 1 dose of Varilrix at Day 42 (Visit 2). Both vaccines were administered subcutaneously in the deltoid region of the left arm.</description>
          </group>
          <group group_id="O3">
            <title>MMR Group</title>
            <description>Subjects in this group received 2 doses of Priorix, administered subcutaneously in the deltoid region of the left arm, one at Day 0 (Visit 1) and the other at Day 42 (Visit 2).</description>
          </group>
        </group_list>
        <measure>
          <title>Phase B: Number of Subjects With Anti-VZV Antibody Concentrations Above the Cut-off Value</title>
          <description>The anti-VZV antibody concentration cut-off value assessed was greater than or equal to (≥) 25 mIU/mL, in the sera of subjects seronegative before vaccination.</description>
          <population>The analysis was performed on the Adapted persistence cohort (Adapted ATP cohort for each specific time point).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1342"/>
                <count group_id="O2" value="1142"/>
                <count group_id="O3" value="242"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-VZV, Year 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1342"/>
                    <count group_id="O2" value="1142"/>
                    <count group_id="O3" value="242"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1330"/>
                    <measurement group_id="O2" value="1061"/>
                    <measurement group_id="O3" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-VZV, Year 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1292"/>
                    <count group_id="O2" value="1021"/>
                    <count group_id="O3" value="176"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1289"/>
                    <measurement group_id="O2" value="986"/>
                    <measurement group_id="O3" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-VZV, Year 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1146"/>
                    <count group_id="O2" value="828"/>
                    <count group_id="O3" value="117"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1142"/>
                    <measurement group_id="O2" value="806"/>
                    <measurement group_id="O3" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-VZV, Year 10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1169"/>
                    <count group_id="O2" value="831"/>
                    <count group_id="O3" value="111"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1164"/>
                    <measurement group_id="O2" value="818"/>
                    <measurement group_id="O3" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase B: Immune Response to Measles With Respect to Anti-measles Antibody Concentrations</title>
        <description>Anti-measles antibody concentrations are presented as Geometric Mean Concentrations (GMCs), expressed in milliinternational units per milliliter (mIU/mL).</description>
        <time_frame>At Year 4, Year 6, Year 8 and Year 10 time points</time_frame>
        <population>The analysis was performed on the Adapted persistence cohort, subset for MMR testing (Adapted ATP cohort for each specific time point).</population>
        <group_list>
          <group group_id="O1">
            <title>MMRV Group</title>
            <description>Subjects in this group received 2 doses of Priorix-Tetra vaccine, administered subcutaneously in the deltoid region of the left arm, one at Day 0 (Visit 1) and the other at Day 42 (Visit 2).</description>
          </group>
          <group group_id="O2">
            <title>OKAH Group</title>
            <description>Subjects in this group received 1 dose of Priorix at Day 0 (Visit 1) and 1 dose of Varilrix at Day 42 (Visit 2). Both vaccines were administered subcutaneously in the deltoid region of the left arm.</description>
          </group>
          <group group_id="O3">
            <title>MMR Group</title>
            <description>Subjects in this group received 2 doses of Priorix, administered subcutaneously in the deltoid region of the left arm, one at Day 0 (Visit 1) and the other at Day 42 (Visit 2).</description>
          </group>
        </group_list>
        <measure>
          <title>Phase B: Immune Response to Measles With Respect to Anti-measles Antibody Concentrations</title>
          <description>Anti-measles antibody concentrations are presented as Geometric Mean Concentrations (GMCs), expressed in milliinternational units per milliliter (mIU/mL).</description>
          <population>The analysis was performed on the Adapted persistence cohort, subset for MMR testing (Adapted ATP cohort for each specific time point).</population>
          <units>mIU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="410"/>
                <count group_id="O2" value="409"/>
                <count group_id="O3" value="137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-measles, Year 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="410"/>
                    <count group_id="O2" value="409"/>
                    <count group_id="O3" value="137"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3290.9" lower_limit="3025.8" upper_limit="3579.2"/>
                    <measurement group_id="O2" value="1803.5" lower_limit="1635.8" upper_limit="1988.5"/>
                    <measurement group_id="O3" value="1724.4" lower_limit="1431.7" upper_limit="2077.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-measles, Year 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="406"/>
                    <count group_id="O2" value="221"/>
                    <count group_id="O3" value="137"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2795.9" lower_limit="2544.7" upper_limit="3072.0"/>
                    <measurement group_id="O2" value="1727.7" lower_limit="1514.3" upper_limit="1971.1"/>
                    <measurement group_id="O3" value="1369.0" lower_limit="1125.7" upper_limit="1665.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-measles, Year 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="357"/>
                    <count group_id="O2" value="125"/>
                    <count group_id="O3" value="119"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2342.0" lower_limit="2115.3" upper_limit="2593.0"/>
                    <measurement group_id="O2" value="1575.1" lower_limit="1296.9" upper_limit="1913.1"/>
                    <measurement group_id="O3" value="1175.5" lower_limit="963.6" upper_limit="1434.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-measles, Year 10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="344"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="116"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1857.2" lower_limit="1664.0" upper_limit="2072.8"/>
                    <measurement group_id="O2" value="997.5" lower_limit="726.7" upper_limit="1369.1"/>
                    <measurement group_id="O3" value="913.6" lower_limit="747.0" upper_limit="1117.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase B: Number of Subjects With Anti-measles Antibody Concentrations Above the Cut-off Value</title>
        <description>The anti-measles antibody concentration cut-off value assessed was ≥ 150 mIU/mL, in the sera of subjects seronegative before vaccination.</description>
        <time_frame>At Year 4, Year 6, Year 8 and Year 10 time points</time_frame>
        <population>The analysis was performed on the Adapted persistence cohort, subset for MMR testing (Adapted ATP cohort for each specific time point).</population>
        <group_list>
          <group group_id="O1">
            <title>MMRV Group</title>
            <description>Subjects in this group received 2 doses of Priorix-Tetra vaccine, administered subcutaneously in the deltoid region of the left arm, one at Day 0 (Visit 1) and the other at Day 42 (Visit 2).</description>
          </group>
          <group group_id="O2">
            <title>OKAH Group</title>
            <description>Subjects in this group received 1 dose of Priorix at Day 0 (Visit 1) and 1 dose of Varilrix at Day 42 (Visit 2). Both vaccines were administered subcutaneously in the deltoid region of the left arm.</description>
          </group>
          <group group_id="O3">
            <title>MMR Group</title>
            <description>Subjects in this group received 2 doses of Priorix, administered subcutaneously in the deltoid region of the left arm, one at Day 0 (Visit 1) and the other at Day 42 (Visit 2).</description>
          </group>
        </group_list>
        <measure>
          <title>Phase B: Number of Subjects With Anti-measles Antibody Concentrations Above the Cut-off Value</title>
          <description>The anti-measles antibody concentration cut-off value assessed was ≥ 150 mIU/mL, in the sera of subjects seronegative before vaccination.</description>
          <population>The analysis was performed on the Adapted persistence cohort, subset for MMR testing (Adapted ATP cohort for each specific time point).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="410"/>
                <count group_id="O2" value="409"/>
                <count group_id="O3" value="137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-measles, Year 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="410"/>
                    <count group_id="O2" value="409"/>
                    <count group_id="O3" value="137"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="407"/>
                    <measurement group_id="O2" value="402"/>
                    <measurement group_id="O3" value="131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-measles, Year 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="406"/>
                    <count group_id="O2" value="221"/>
                    <count group_id="O3" value="137"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="402"/>
                    <measurement group_id="O2" value="218"/>
                    <measurement group_id="O3" value="128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-measles, Year 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="357"/>
                    <count group_id="O2" value="125"/>
                    <count group_id="O3" value="119"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="353"/>
                    <measurement group_id="O2" value="121"/>
                    <measurement group_id="O3" value="113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-measles, Year 10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="344"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="116"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="339"/>
                    <measurement group_id="O2" value="39"/>
                    <measurement group_id="O3" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase B: Immune Response to Mumps With Respect to Anti-mumps Antibody Concentrations</title>
        <description>Anti-mumps antibody concentrations are presented as Geometric Mean Concentrations (GMCs), expressed in units per milliliter (U/mL).</description>
        <time_frame>At Year 4, Year 6, Year 8 and Year 10 time points</time_frame>
        <population>The analysis was performed on the Adapted persistence cohort, subset for MMR testing (Adapted ATP cohort for each specific time point).</population>
        <group_list>
          <group group_id="O1">
            <title>MMRV Group</title>
            <description>Subjects in this group received 2 doses of Priorix-Tetra vaccine, administered subcutaneously in the deltoid region of the left arm, one at Day 0 (Visit 1) and the other at Day 42 (Visit 2).</description>
          </group>
          <group group_id="O2">
            <title>OKAH Group</title>
            <description>Subjects in this group received 1 dose of Priorix at Day 0 (Visit 1) and 1 dose of Varilrix at Day 42 (Visit 2). Both vaccines were administered subcutaneously in the deltoid region of the left arm.</description>
          </group>
          <group group_id="O3">
            <title>MMR Group</title>
            <description>Subjects in this group received 2 doses of Priorix, administered subcutaneously in the deltoid region of the left arm, one at Day 0 (Visit 1) and the other at Day 42 (Visit 2).</description>
          </group>
        </group_list>
        <measure>
          <title>Phase B: Immune Response to Mumps With Respect to Anti-mumps Antibody Concentrations</title>
          <description>Anti-mumps antibody concentrations are presented as Geometric Mean Concentrations (GMCs), expressed in units per milliliter (U/mL).</description>
          <population>The analysis was performed on the Adapted persistence cohort, subset for MMR testing (Adapted ATP cohort for each specific time point).</population>
          <units>U/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="407"/>
                <count group_id="O2" value="407"/>
                <count group_id="O3" value="136"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-mumps, Year 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="407"/>
                    <count group_id="O2" value="407"/>
                    <count group_id="O3" value="136"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1088.9" lower_limit="974.9" upper_limit="1216.3"/>
                    <measurement group_id="O2" value="905.3" lower_limit="810.0" upper_limit="1011.9"/>
                    <measurement group_id="O3" value="1059.1" lower_limit="878.9" upper_limit="1276.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-mumps, Year 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="398"/>
                    <count group_id="O2" value="217"/>
                    <count group_id="O3" value="132"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="999.7" lower_limit="897.4" upper_limit="1113.7"/>
                    <measurement group_id="O2" value="920.5" lower_limit="800.3" upper_limit="1058.8"/>
                    <measurement group_id="O3" value="1030.3" lower_limit="879.1" upper_limit="1207.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-mumps, Year 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="348"/>
                    <count group_id="O2" value="120"/>
                    <count group_id="O3" value="117"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="875.7" lower_limit="781.9" upper_limit="980.9"/>
                    <measurement group_id="O2" value="865.7" lower_limit="718.3" upper_limit="1043.3"/>
                    <measurement group_id="O3" value="869.1" lower_limit="723.3" upper_limit="1044.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-mumps, Year 10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="339"/>
                    <count group_id="O2" value="37"/>
                    <count group_id="O3" value="115"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="889.3" lower_limit="794.4" upper_limit="995.6"/>
                    <measurement group_id="O2" value="1054.0" lower_limit="797.2" upper_limit="1393.6"/>
                    <measurement group_id="O3" value="912.7" lower_limit="759.5" upper_limit="1096.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase B: Number of Subjects With Anti-mumps Antibody Concentrations Above the Cut-off Value</title>
        <description>The anti-mumps antibody concentration cut-off value assessed was ≥ 231 U/mL, in the sera of subjects seronegative before vaccination.</description>
        <time_frame>At Year 4, Year 6, Year 8 and Year 10 time points</time_frame>
        <population>The analysis was performed on the Adapted persistence cohort, subset for MMR testing (Adapted ATP cohort for each specific time point).</population>
        <group_list>
          <group group_id="O1">
            <title>MMRV Group</title>
            <description>Subjects in this group received 2 doses of Priorix-Tetra vaccine, administered subcutaneously in the deltoid region of the left arm, one at Day 0 (Visit 1) and the other at Day 42 (Visit 2).</description>
          </group>
          <group group_id="O2">
            <title>OKAH Group</title>
            <description>Subjects in this group received 1 dose of Priorix at Day 0 (Visit 1) and 1 dose of Varilrix at Day 42 (Visit 2). Both vaccines were administered subcutaneously in the deltoid region of the left arm.</description>
          </group>
          <group group_id="O3">
            <title>MMR Group</title>
            <description>Subjects in this group received 2 doses of Priorix, administered subcutaneously in the deltoid region of the left arm, one at Day 0 (Visit 1) and the other at Day 42 (Visit 2).</description>
          </group>
        </group_list>
        <measure>
          <title>Phase B: Number of Subjects With Anti-mumps Antibody Concentrations Above the Cut-off Value</title>
          <description>The anti-mumps antibody concentration cut-off value assessed was ≥ 231 U/mL, in the sera of subjects seronegative before vaccination.</description>
          <population>The analysis was performed on the Adapted persistence cohort, subset for MMR testing (Adapted ATP cohort for each specific time point).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="407"/>
                <count group_id="O2" value="407"/>
                <count group_id="O3" value="136"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-mumps, Year 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="407"/>
                    <count group_id="O2" value="407"/>
                    <count group_id="O3" value="136"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="368"/>
                    <measurement group_id="O2" value="357"/>
                    <measurement group_id="O3" value="123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-mumps, Year 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="398"/>
                    <count group_id="O2" value="217"/>
                    <count group_id="O3" value="132"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="360"/>
                    <measurement group_id="O2" value="196"/>
                    <measurement group_id="O3" value="127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-mumps, Year 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="348"/>
                    <count group_id="O2" value="120"/>
                    <count group_id="O3" value="117"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="305"/>
                    <measurement group_id="O2" value="107"/>
                    <measurement group_id="O3" value="108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-mumps, Year 10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="339"/>
                    <count group_id="O2" value="37"/>
                    <count group_id="O3" value="115"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="305"/>
                    <measurement group_id="O2" value="36"/>
                    <measurement group_id="O3" value="108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase B: Immune Response to Rubella With Respect to Anti-rubella Antibody Concentrations</title>
        <description>Anti-rubella antibody concentrations are presented as Geometric Mean Concentrations (GMCs), expressed in international units per milliliter (IU/mL).</description>
        <time_frame>At Year 4, Year 6, Year 8 and Year 10 time points</time_frame>
        <population>The analysis was performed on the Adapted persistence cohort, subset for MMR testing (Adapted ATP cohort for each specific time point).</population>
        <group_list>
          <group group_id="O1">
            <title>MMRV Group</title>
            <description>Subjects in this group received 2 doses of Priorix-Tetra vaccine, administered subcutaneously in the deltoid region of the left arm, one at Day 0 (Visit 1) and the other at Day 42 (Visit 2).</description>
          </group>
          <group group_id="O2">
            <title>OKAH Group</title>
            <description>Subjects in this group received 1 dose of Priorix at Day 0 (Visit 1) and 1 dose of Varilrix at Day 42 (Visit 2). Both vaccines were administered subcutaneously in the deltoid region of the left arm.</description>
          </group>
          <group group_id="O3">
            <title>MMR Group</title>
            <description>Subjects in this group received 2 doses of Priorix, administered subcutaneously in the deltoid region of the left arm, one at Day 0 (Visit 1) and the other at Day 42 (Visit 2).</description>
          </group>
        </group_list>
        <measure>
          <title>Phase B: Immune Response to Rubella With Respect to Anti-rubella Antibody Concentrations</title>
          <description>Anti-rubella antibody concentrations are presented as Geometric Mean Concentrations (GMCs), expressed in international units per milliliter (IU/mL).</description>
          <population>The analysis was performed on the Adapted persistence cohort, subset for MMR testing (Adapted ATP cohort for each specific time point).</population>
          <units>IU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="407"/>
                <count group_id="O2" value="410"/>
                <count group_id="O3" value="137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-rubella, Year 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="407"/>
                    <count group_id="O2" value="410"/>
                    <count group_id="O3" value="137"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.4" lower_limit="40.9" upper_limit="48.3"/>
                    <measurement group_id="O2" value="50.8" lower_limit="46.8" upper_limit="55.2"/>
                    <measurement group_id="O3" value="49.0" lower_limit="42.9" upper_limit="55.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-rubella, Year 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="403"/>
                    <count group_id="O2" value="224"/>
                    <count group_id="O3" value="137"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.1" lower_limit="27.9" upper_limit="32.4"/>
                    <measurement group_id="O2" value="34.0" lower_limit="30.6" upper_limit="37.7"/>
                    <measurement group_id="O3" value="33.3" lower_limit="29.2" upper_limit="37.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-rubella, Year 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="354"/>
                    <count group_id="O2" value="124"/>
                    <count group_id="O3" value="119"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.8" lower_limit="19.0" upper_limit="22.9"/>
                    <measurement group_id="O2" value="26.7" lower_limit="22.7" upper_limit="31.5"/>
                    <measurement group_id="O3" value="23.3" lower_limit="19.8" upper_limit="27.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-rubella, Year 10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="342"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="116"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.8" lower_limit="17.0" upper_limit="20.7"/>
                    <measurement group_id="O2" value="29.2" lower_limit="22.7" upper_limit="37.7"/>
                    <measurement group_id="O3" value="20.8" lower_limit="17.6" upper_limit="24.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase B: Number of Subjects With Anti-rubella Antibody Concentrations Above the Cut-off Value</title>
        <description>The anti-rubella antibody concentration cut-off value assessed was ≥ 4 IU/mL, in the sera of subjects seronegative before vaccination.</description>
        <time_frame>At Year 4, Year 6, Year 8 and Year 10 time points</time_frame>
        <population>The analysis was performed on the Adapted persistence cohort, subset for MMR testing (Adapted ATP cohort for each specific time point).</population>
        <group_list>
          <group group_id="O1">
            <title>MMRV Group</title>
            <description>Subjects in this group received 2 doses of Priorix-Tetra vaccine, administered subcutaneously in the deltoid region of the left arm, one at Day 0 (Visit 1) and the other at Day 42 (Visit 2).</description>
          </group>
          <group group_id="O2">
            <title>OKAH Group</title>
            <description>Subjects in this group received 1 dose of Priorix at Day 0 (Visit 1) and 1 dose of Varilrix at Day 42 (Visit 2). Both vaccines were administered subcutaneously in the deltoid region of the left arm.</description>
          </group>
          <group group_id="O3">
            <title>MMR Group</title>
            <description>Subjects in this group received 2 doses of Priorix, administered subcutaneously in the deltoid region of the left arm, one at Day 0 (Visit 1) and the other at Day 42 (Visit 2).</description>
          </group>
        </group_list>
        <measure>
          <title>Phase B: Number of Subjects With Anti-rubella Antibody Concentrations Above the Cut-off Value</title>
          <description>The anti-rubella antibody concentration cut-off value assessed was ≥ 4 IU/mL, in the sera of subjects seronegative before vaccination.</description>
          <population>The analysis was performed on the Adapted persistence cohort, subset for MMR testing (Adapted ATP cohort for each specific time point).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="407"/>
                <count group_id="O2" value="410"/>
                <count group_id="O3" value="137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Anti-rubella, Year 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="407"/>
                    <count group_id="O2" value="410"/>
                    <count group_id="O3" value="137"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="407"/>
                    <measurement group_id="O2" value="408"/>
                    <measurement group_id="O3" value="137"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-rubella, Year 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="403"/>
                    <count group_id="O2" value="224"/>
                    <count group_id="O3" value="137"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="402"/>
                    <measurement group_id="O2" value="222"/>
                    <measurement group_id="O3" value="136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-rubella, Year 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="354"/>
                    <count group_id="O2" value="124"/>
                    <count group_id="O3" value="119"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="347"/>
                    <measurement group_id="O2" value="120"/>
                    <measurement group_id="O3" value="116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anti-rubella, Year 10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="342"/>
                    <count group_id="O2" value="39"/>
                    <count group_id="O3" value="116"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="334"/>
                    <measurement group_id="O2" value="39"/>
                    <measurement group_id="O3" value="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase B: Characteristics of Zoster Cases</title>
        <description>Zoster cases were characterized by number and character of lesions, duration of rash, incidence of fever, systemic signs, the assessment by investigator, complications, treatment, outcome and intensity of severity.</description>
        <time_frame>From 6 weeks after Dose 2 until study end (Year 10)</time_frame>
        <population>The analysis was performed on the ATP Cohort for Efficacy (Phase A), which included all evaluable subjects who had efficacy follow-up starting from 42 days post dose 2 and from the period when Phase A was completed.</population>
        <group_list>
          <group group_id="O1">
            <title>OKAH Group</title>
            <description>Subjects in this group received 1 dose of Priorix at Day 0 (Visit 1) and 1 dose of Varilrix at Day 42 (Visit 2). Both vaccines were administered subcutaneously in the deltoid region of the left arm.</description>
          </group>
          <group group_id="O2">
            <title>MMR Group</title>
            <description>Subjects in this group received 2 doses of Priorix, administered subcutaneously in the deltoid region of the left arm, one at Day 0 (Visit 1) and the other at Day 42 (Visit 2).</description>
          </group>
        </group_list>
        <measure>
          <title>Phase B: Characteristics of Zoster Cases</title>
          <description>Zoster cases were characterized by number and character of lesions, duration of rash, incidence of fever, systemic signs, the assessment by investigator, complications, treatment, outcome and intensity of severity.</description>
          <population>The analysis was performed on the ATP Cohort for Efficacy (Phase A), which included all evaluable subjects who had efficacy follow-up starting from 42 days post dose 2 and from the period when Phase A was completed.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Rash: number of lesions, 1-50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash: number of lesions, 51-100</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash: number of lesions, 101-500</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rash: number of lesions, 501+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Character of most lesions, Macular</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Character of most lesions, Papular</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Character of most lesions, Vesicular</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Character of most lesions, Haemorrhagic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration of rash, 0 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration of rash, 1-5 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration of rash, 6-10 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration of rash, 11-15 days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Duration of rash, 16+ days</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Max. number of lesions [investigator], 1-50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Max. number of lesions [investigator], 51-100</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Max. number of lesions [investigator], 101-500</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Max. number of lesions [investigator], 501+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever, No fever</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever, 38.8°C to 39.9°C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever, 40+ °C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systemic signs, Pain in back or abdomen</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systemic signs, Interstitial pneumonia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systemic signs, Encephalitis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Assessment by investigator, Does not appear ill</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Assessment by investigator, Moderately ill</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Assessment by investigator, Severely ill</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complications, Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complications, No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment, Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment, No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Outcome, Recovered/resolved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Outcome, Recovered/resolved with sequelae</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intensity of severity, Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intensity of severity, Moderately severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intensity of severity, Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase B: Number of Subjects Reporting Serious Adverse Events (SAEs)</title>
        <description>SAEs assessed included medical occurrences that resulted in death, were life-threatening, required hospitalisation or prolongation of hospitalisation or resulted in disability/incapacity. Any SAE = occurrence of SAE regardless of intensity grade or relation to vaccination.</description>
        <time_frame>From the beginning of Phase B (Year 2) up to study end (Year 10)</time_frame>
        <population>The analysis was performed on the Total enrolled cohort in Phase B, which included all subjects from the Total Vaccinated cohort in Phase A who returned for at least one visit in Phase B</population>
        <group_list>
          <group group_id="O1">
            <title>MMRV Group</title>
            <description>Subjects in this group received 2 doses of Priorix-Tetra vaccine, administered subcutaneously in the deltoid region of the left arm, one at Day 0 (Visit 1) and the other at Day 42 (Visit 2).</description>
          </group>
          <group group_id="O2">
            <title>OKAH Group</title>
            <description>Subjects in this group received 1 dose of Priorix at Day 0 (Visit 1) and 1 dose of Varilrix at Day 42 (Visit 2). Both vaccines were administered subcutaneously in the deltoid region of the left arm.</description>
          </group>
          <group group_id="O3">
            <title>MMR Group</title>
            <description>Subjects in this group received 2 doses of Priorix, administered subcutaneously in the deltoid region of the left arm, one at Day 0 (Visit 1) and the other at Day 42 (Visit 2).</description>
          </group>
        </group_list>
        <measure>
          <title>Phase B: Number of Subjects Reporting Serious Adverse Events (SAEs)</title>
          <description>SAEs assessed included medical occurrences that resulted in death, were life-threatening, required hospitalisation or prolongation of hospitalisation or resulted in disability/incapacity. Any SAE = occurrence of SAE regardless of intensity grade or relation to vaccination.</description>
          <population>The analysis was performed on the Total enrolled cohort in Phase B, which included all subjects from the Total Vaccinated cohort in Phase A who returned for at least one visit in Phase B</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1961"/>
                <count group_id="O2" value="1978"/>
                <count group_id="O3" value="641"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="290"/>
                    <measurement group_id="O2" value="317"/>
                    <measurement group_id="O3" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase B: Health Economics Analysis of Factors Leading to Indirect Costs Due to Varicella Illness</title>
        <description>Parameters assessed: 1. Number of hours lost from work by parents/guardians as a result of taking care of their child due to varicella. 2. Number of hours the child lost attendance in: day care/childminder, school, or in any extra-curricular activities (e.g. sports or recreation or any type of organised leisure activities) due to varicella. 3. Number of hours spent by a nurse, a babysitter or any type of existing paid caregiver to look after the child (if applicable).</description>
        <time_frame>During Phase B</time_frame>
        <population>The analysis was performed on the ATP Cohort for Efficacy (Phase B), which included all evaluable subjects who had efficacy follow-up from the period when Phase A was completed.</population>
        <group_list>
          <group group_id="O1">
            <title>MMRV Group</title>
            <description>Subjects in this group received 2 doses of Priorix-Tetra vaccine, administered subcutaneously in the deltoid region of the left arm, one at Day 0 (Visit 1) and the other at Day 42 (Visit 2).</description>
          </group>
          <group group_id="O2">
            <title>OKAH Group</title>
            <description>Subjects in this group received 1 dose of Priorix at Day 0 (Visit 1) and 1 dose of Varilrix at Day 42 (Visit 2). Both vaccines were administered subcutaneously in the deltoid region of the left arm.</description>
          </group>
          <group group_id="O3">
            <title>MMR Group</title>
            <description>Subjects in this group received 2 doses of Priorix, administered subcutaneously in the deltoid region of the left arm, one at Day 0 (Visit 1) and the other at Day 42 (Visit 2).</description>
          </group>
        </group_list>
        <measure>
          <title>Phase B: Health Economics Analysis of Factors Leading to Indirect Costs Due to Varicella Illness</title>
          <description>Parameters assessed: 1. Number of hours lost from work by parents/guardians as a result of taking care of their child due to varicella. 2. Number of hours the child lost attendance in: day care/childminder, school, or in any extra-curricular activities (e.g. sports or recreation or any type of organised leisure activities) due to varicella. 3. Number of hours spent by a nurse, a babysitter or any type of existing paid caregiver to look after the child (if applicable).</description>
          <population>The analysis was performed on the ATP Cohort for Efficacy (Phase B), which included all evaluable subjects who had efficacy follow-up from the period when Phase A was completed.</population>
          <units>Hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="227"/>
                <count group_id="O3" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Time lost from work [hours]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.8" spread="44.1"/>
                    <measurement group_id="O2" value="44.6" spread="31.1"/>
                    <measurement group_id="O3" value="57.8" spread="36.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time lost for subjects [hours]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.7" spread="35.6"/>
                    <measurement group_id="O2" value="48.0" spread="34.1"/>
                    <measurement group_id="O3" value="57.2" spread="36.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Time of requested assistance [hours]</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="45.7" spread="21.5"/>
                    <measurement group_id="O3" value="49.4" spread="50.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Solicited local AEs: 4-days (Days 0-3) post dose 1 (Day 0) and dose 2 (Day 42). Solicited general and unsolicited AEs: 43-days (Days 0-42) post dose 1 (Day 0) and dose 2 (Day 42). Serious adverse events: From Day 0 up to the end of study (Year 10).</time_frame>
      <desc>For the systematically assessed other (non-serious) adverse events, the number of participants at risk included those from Total Vaccinated Cohort who had the symptom sheet completed</desc>
      <group_list>
        <group group_id="E1">
          <title>MMRV Group</title>
          <description>Subjects in this group received 2 doses of Priorix-Tetra vaccine, administered subcutaneously in the deltoid region of the left arm, one at Day 0 (Visit 1) and the other at Day 42 (Visit 2).</description>
        </group>
        <group group_id="E2">
          <title>OKAH Group</title>
          <description>Subjects in this group received 1 dose of Priorix at Day 0 (Visit 1) and 1 dose of Varilrix at Day 42 (Visit 2). Both vaccines were administered subcutaneously in the deltoid region of the left arm.</description>
        </group>
        <group group_id="E3">
          <title>MMR Group</title>
          <description>Subjects in this group received 2 doses of Priorix, administered subcutaneously in the deltoid region of the left arm, one at Day 0 (Visit 1) and the other at Day 42 (Visit 2).</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 12.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="649" subjects_at_risk="2489"/>
                <counts group_id="E2" subjects_affected="681" subjects_at_risk="2487"/>
                <counts group_id="E3" subjects_affected="208" subjects_at_risk="827"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal lymphadenopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="2489"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Haemorrhagic diathesis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Immune thrombocytopenic purpura</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2489"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Lymphadenitis</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="2489"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="2487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Arrhythmia supraventricular</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Cyanosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Long qt syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Anomaly of external ear congenital</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Atrial septal defect</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Choledochal cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Congenital cystic kidney disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Congenital inguinal hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Congenital oral malformation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Cryptorchism</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="2489"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Cystic fibrosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Double ureter</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Duane's syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Hereditary pancreatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="5" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Hernia congenital</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Hydrocele</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="2489"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Neurofibromatosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Phimosis</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="2489"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="2487"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Primary ciliary dyskinesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Thalassaemia beta</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear deformity acquired</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>External ear disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Hypoacusis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Inner ear disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Otorrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="827"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Endocrine disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Thyroiditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="827"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Astigmatism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Chalazion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Eye haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Eyelid oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Inflammation of lacrimal passage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Papilloedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Strabismus</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2489"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Visual impairment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="2489"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="2487"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Anal fissure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Anal stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Aphthous ulcer</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="2489"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Coeliac disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2489"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="2487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Diarrhoea haemorrhagic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Duodenitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="2489"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="2489"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="2487"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="2489"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Functional gastrointestinal disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="34" subjects_affected="31" subjects_at_risk="2489"/>
                <counts group_id="E2" events="25" subjects_affected="22" subjects_at_risk="2487"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Gastritis erosive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Gastroduodenitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Gastrointestinal inflammation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="2489"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="2487"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Intestinal haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Intussusception</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Large intestine polyp</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Lip disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Teething</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Tooth loss</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="2489"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="2487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="2489"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="827"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Accidental death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Crying</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Granuloma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Hyperpyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Hyperthermia malignant</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Ill-defined disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Polyp</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="2489"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Soft tissue inflammation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Bile duct obstruction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Gallbladder disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Liver disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Allergy to arthropod sting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Anaphylactoid reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Atopy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2489"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Immunodeficiency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abscess neck</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="2487"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Adenoiditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Adenovirus infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="2489"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="2487"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Ascariasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Bacterial diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Bacterial infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Bacteriuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Body tinea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Borrelia infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="55" subjects_affected="47" subjects_at_risk="2489"/>
                <counts group_id="E2" events="65" subjects_affected="51" subjects_at_risk="2487"/>
                <counts group_id="E3" events="15" subjects_affected="15" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Bronchitis haemophilus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Campylobacter gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Campylobacter infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Cellulitis orbital</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Chronic tonsillitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="2489"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="2487"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Croup infectious</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="2489"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="2487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Diarrhoea infectious</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="2489"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Eczema impetiginous</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Encephalitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Enteritis infectious</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="2489"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="2487"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Enterobiasis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Enterocolitis infectious</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Enterovirus infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Epididymitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Epstein-barr virus infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Erythema infectiosum</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Escherichia urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Exanthema subitum</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Eye infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Febrile infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Gastritis viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="74" subjects_affected="67" subjects_at_risk="2489"/>
                <counts group_id="E2" events="79" subjects_affected="71" subjects_at_risk="2487"/>
                <counts group_id="E3" events="28" subjects_affected="26" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Gastroenteritis adenovirus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Gastroenteritis bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Gastroenteritis norovirus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Gastroenteritis rotavirus</sub_title>
                <counts group_id="E1" events="27" subjects_affected="27" subjects_at_risk="2489"/>
                <counts group_id="E2" events="42" subjects_affected="42" subjects_at_risk="2487"/>
                <counts group_id="E3" events="13" subjects_affected="13" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Gastroenteritis salmonella</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2489"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2489"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="2487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Gastrointestinal bacterial overgrowth</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Gastrointestinal infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Gastrointestinal viral infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>H1n1 influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Helicobacter gastritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Hepatitis a</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Herpangina</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Herpes simplex</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Infectious mononucleosis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="2489"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2489"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" events="51" subjects_affected="39" subjects_at_risk="2489"/>
                <counts group_id="E2" events="56" subjects_affected="45" subjects_at_risk="2487"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Mastoiditis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Meningitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2489"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Meningitis aseptic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Meningitis borrelia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Meningococcal sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Molluscum contagiosum</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2489"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Nasal abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="2489"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="2487"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Neuroborreliosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2489"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="2487"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Orchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Oropharyngitis fungal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" events="19" subjects_affected="17" subjects_at_risk="2489"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="2487"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Otitis media acute</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="2489"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Otitis media chronic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Overgrowth bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Parotitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Parvovirus b19 infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Periodontitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Peritonsillar abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="21" subjects_affected="20" subjects_at_risk="2489"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="2487"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Pharyngitis streptococcal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Pharyngotonsillitis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="2489"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="2487"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Pilonidal cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="80" subjects_affected="70" subjects_at_risk="2489"/>
                <counts group_id="E2" events="66" subjects_affected="63" subjects_at_risk="2487"/>
                <counts group_id="E3" events="31" subjects_affected="30" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Pneumonia pneumococcal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Pneumonia viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Pseudocroup</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2489"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="2489"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="2487"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="2489"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="2487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Pyoderma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="2489"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="2487"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Rotavirus infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Salmonellosis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="2489"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Scarlet fever</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="2489"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="2487"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Staphylococcal bacteraemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" events="23" subjects_affected="23" subjects_at_risk="2489"/>
                <counts group_id="E2" events="19" subjects_affected="18" subjects_at_risk="2487"/>
                <counts group_id="E3" events="9" subjects_affected="7" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Tonsillitis bacterial</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Tonsillitis streptococcal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Toxocariasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Tracheitis</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="2489"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="2487"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Tracheobronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="2487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Tuberculosis of intrathoracic lymph nodes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="2489"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="2487"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="2489"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="2487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Varicella</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Viral diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="2489"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="2487"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Viral myositis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Viral pharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Viral tonsillitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="2489"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="2487"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Vulvitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="827"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Abdominal injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Accidental exposure to product</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="2489"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="2487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Animal bite</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Arthropod sting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Bite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Brain contusion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Burn oral cavity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Burns second degree</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Carbon monoxide poisoning</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2489"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Chemical injury</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Chemical poisoning</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Child maltreatment syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" events="24" subjects_affected="23" subjects_at_risk="2489"/>
                <counts group_id="E2" events="26" subjects_affected="26" subjects_at_risk="2487"/>
                <counts group_id="E3" events="8" subjects_affected="7" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="2489"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="2487"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Dislocation of vertebra</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Exposure to toxic agent</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Eye contusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Eye injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Facial bones fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2489"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="2487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Forearm fracture</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="2489"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Foreign body</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="2489"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="2487"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Foreign body aspiration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Fracture displacement</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="2489"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Heat stroke</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="2489"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Jaw fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Kidney contusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Liver contusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Multiple injuries</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Nasal injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Near drowning</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Neck injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Open fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Pancreatic injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Patella fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Penile contusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Poisoning</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Poisoning deliberate</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="2489"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="2487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Skin wound</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Skull fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Struck by lightning</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="2489"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="2487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Thoracic vertebral fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Tongue injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Tooth injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Toxicity to various agents</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2489"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2487"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Ulna fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="2487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Venomous sting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="2489"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Medical observation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" events="6" subjects_affected="2" subjects_at_risk="2489"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="2487"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="5" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="4" subjects_affected="1" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Diabetic ketoacidosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2489"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Ketoacidosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Lactose intolerance</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Metabolic acidosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Obesity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Type 1 diabetes mellitus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="2487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Weight gain poor</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="2489"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="2487"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Arthritis reactive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Arthropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Bone disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Exostosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Fistula</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Growth retardation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Joint effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Juvenile idiopathic arthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Myopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Myositis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Osteochondrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Periostitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Rickets</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Sacroiliitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Scoliosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Spinal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Synovitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Torticollis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Trigger finger</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Acute leukaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Acute lymphocytic leukaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Acute lymphocytic leukaemia recurrent</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Astrocytoma, low grade</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Benign bone neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Laryngeal papilloma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Lipoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Medulloblastoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Melanocytic naevus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Myelodysplastic syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Nephroblastoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Neuroblastoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Osteochondroma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Ovarian germ cell teratoma benign</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Papilloma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Rhabdomyosarcoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Skin papilloma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Teratoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Autism</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Benign rolandic epilepsy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Brain injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Cluster headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Coordination abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Dysgraphia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Dyslexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="2489"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="2487"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Facial paralysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Facial paresis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Febrile convulsion</sub_title>
                <counts group_id="E1" events="23" subjects_affected="21" subjects_at_risk="2489"/>
                <counts group_id="E2" events="23" subjects_affected="20" subjects_at_risk="2487"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2489"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="2487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Intellectual disability</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Language disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Loss of consciousness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Nervous system disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Paraparesis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Peripheral nerve palsy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Polyneuropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Postictal state</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="2487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Speech disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Speech disorder developmental</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2489"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="2487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="827"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal behaviour</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Adjustment disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Adjustment disorder with mixed anxiety and depressed mood</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Affective disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Attention deficit/hyperactivity disorder</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="2489"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Breath holding</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Enuresis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Learning disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Mental disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Neurosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Nightmare</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Psychomotor retardation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Reading disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Tic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Glomerulonephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Glomerulonephritis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Glomerulonephritis chronic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Micturition disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Nephritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Renal haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Tubulointerstitial nephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Vesicoureteric reflux</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Acquired phimosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Balanoposthitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Penile adhesion</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="2489"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="2487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Penis disorder</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Testicular appendage torsion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Testicular atrophy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Testicular disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Testicular retraction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Adenoidal hypertrophy</sub_title>
                <counts group_id="E1" events="116" subjects_affected="111" subjects_at_risk="2489"/>
                <counts group_id="E2" events="129" subjects_affected="123" subjects_at_risk="2487"/>
                <counts group_id="E3" events="39" subjects_affected="39" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Asphyxia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="2489"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="2487"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Asthmatic crisis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Hyperventilation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Laryngeal obstruction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2489"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Laryngeal oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Laryngospasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Status asthmaticus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Tonsillar hypertrophy</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="2489"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="2487"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Vocal cord thickening</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="2489"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="2487"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Dermatitis atopic</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="2489"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Drug eruption</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Erythema nodosum</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Henoch-schonlein purpura</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Prurigo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Rash papular</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Rash vesicular</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Skin burning sensation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Skin hyperpigmentation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Toxic skin eruption</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="2489"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2487"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="827"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Circumcision</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Kawasaki's disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="2489"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Vasculitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="2489"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2487"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="827"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>4.98</frequency_threshold>
        <default_vocab>MedDRA 12.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="666" subjects_at_risk="2489"/>
                <counts group_id="E2" subjects_affected="641" subjects_at_risk="2487"/>
                <counts group_id="E3" subjects_affected="204" subjects_at_risk="827"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="325" subjects_affected="244" subjects_at_risk="2489"/>
                <counts group_id="E2" events="260" subjects_affected="183" subjects_at_risk="2487"/>
                <counts group_id="E3" events="60" subjects_affected="43" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="849" subjects_affected="604" subjects_at_risk="2489"/>
                <counts group_id="E2" events="790" subjects_affected="574" subjects_at_risk="2487"/>
                <counts group_id="E3" events="253" subjects_affected="188" subjects_at_risk="827"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="165" subjects_affected="124" subjects_at_risk="2489"/>
                <counts group_id="E2" events="146" subjects_affected="111" subjects_at_risk="2487"/>
                <counts group_id="E3" events="37" subjects_affected="31" subjects_at_risk="827"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

